Thoracic aortic aneurysm (TAA) is a localized, permanent dilatation of the thoracic aorta — aortic root, ascending aorta, arch, or descending thoracic aorta. It is usually asymptomatic and detected incidentally on cross-sectional imaging or echocardiography, enlarging silently until it dissects or ruptures. Whatever the upstream cause, the converging tissue lesion is non-inflammatory medial degeneration: loss of vascular smooth muscle cell nuclei, fragmentation and loss of elastic fibers, and mucoid extracellular matrix accumulation in the media. The weakened wall dilates under pulsatile stress in a self-reinforcing Laplace cycle until wall stress exceeds wall strength. TAA is segment-heterogeneous: root and ascending aneurysms occur in younger patients and are enriched for heritable aortopathy and bicuspid-aortic-valve hemodynamic disease, whereas descending thoracic aneurysms occur in older, usually hypertensive patients and reflect an aging/degenerative process. Management centers on blood-pressure and wall-stress reduction, serial imaging surveillance, and prophylactic open or endovascular repair once diameter, size-index, growth-rate, or syndromic risk thresholds are met — though a majority of acute dissections occur below the operative diameter threshold, which is the central unsolved problem in the disease.
Ask a research question about Thoracic Aortic Aneurysm. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Thoracic Aortic Aneurysm
creation_date: "2026-07-31T00:00:00Z"
description: >-
Thoracic aortic aneurysm (TAA) is a localized, permanent dilatation of the
thoracic aorta — aortic root, ascending aorta, arch, or descending thoracic
aorta. It is usually asymptomatic and detected incidentally on cross-sectional
imaging or echocardiography, enlarging silently until it dissects or ruptures.
Whatever the upstream cause, the converging tissue lesion is non-inflammatory
medial degeneration: loss of vascular smooth muscle cell nuclei, fragmentation
and loss of elastic fibers, and mucoid extracellular matrix accumulation in
the media. The weakened wall dilates under pulsatile stress in a
self-reinforcing Laplace cycle until wall stress exceeds wall strength.
TAA is segment-heterogeneous: root and ascending aneurysms occur in younger
patients and are enriched for heritable aortopathy and bicuspid-aortic-valve
hemodynamic disease, whereas descending thoracic aneurysms occur in older,
usually hypertensive patients and reflect an aging/degenerative process.
Management centers on blood-pressure and wall-stress reduction, serial imaging
surveillance, and prophylactic open or endovascular repair once diameter,
size-index, growth-rate, or syndromic risk thresholds are met — though a
majority of acute dissections occur below the operative diameter threshold,
which is the central unsolved problem in the disease.
category: Complex
disease_term:
preferred_term: thoracic aortic aneurysm
term:
id: MONDO:0005396
label: thoracic aortic aneurysm
synonyms:
- TAA
- aneurysm of the thoracic aorta
- ascending thoracic aortic aneurysm
- descending thoracic aortic aneurysm
- degenerative thoracic aortic aneurysm
parents:
- Vascular disorder
classifications:
harrisons_chapter:
- classification_value: CARDIOVASCULAR
references:
- reference: PMID:20301299
title: "Heritable Thoracic Aortic Disease Overview."
tags:
- GeneReviews
prevalence:
- population: Olmsted County, Minnesota, USA (1980-1994; degenerative thoracic aortic aneurysm)
measure_type: ANNUAL_INCIDENCE
prevalence_class: BAND_1_9_PER_100000
rate_per_100000: 10.4
rate_low: 8.6
rate_high: 12.2
notes: >-
Population-based incidence of clinically recognized degenerative thoracic
aortic aneurysm, 10.4 per 100,000 person-years (95% CI 8.6-12.2). More than
3-fold higher than the 1951-1980 rate from the same population, reflecting
increased incidental detection by cross-sectional imaging rather than a
true rise in disease burden.
evidence:
- reference: PMID:9851478
reference_title: "Improved prognosis of thoracic aortic aneurysms: a population-based study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The overall incidence rate of 10.4 per 100000 person-years
explanation: >-
Reports the population-based annual incidence of degenerative thoracic
aortic aneurysm in the Olmsted County cohort. The source gives the
confidence interval as 8.6-12.2 and notes the rate was more than 3-fold
higher than in 1951-1980.
pathophysiology:
- name: Aortic wall aging and chronic hemodynamic stress
description: >-
Cumulative pulsatile wall stress across a lifetime, amplified by systemic
hypertension, drives a vasculopathic aging process in the aortic media.
This is the dominant upstream trigger for sporadic degenerative thoracic
aortic aneurysm, and is especially characteristic of descending thoracic
disease in older patients. It is the acquired counterpart of the monogenic
wall defects that trigger the heritable aortopathies.
role: trigger
biological_scale: TISSUE
cell_types:
- preferred_term: vascular associated smooth muscle cell
term:
id: CL:0000359
label: vascular associated smooth muscle cell
biological_processes:
- preferred_term: extracellular matrix organization
modifier: DECREASED
term:
id: GO:0030198
label: extracellular matrix organization
evidence:
- reference: PMID:27031798
reference_title: "Consensus statement on surgical pathology of the aorta from the Society for Cardiovascular Pathology and the Association For European Cardiovascular Pathology: II. Noninflammatory degenerative diseases - nomenclature and diagnostic criteria."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
A number of diseases, genetic syndromes (Marfan syndrome, Loeys-Dietz
syndrome, etc.), and vasculopathic aging processes involved in vascular
injury can cause both distinct and nonspecific histopathologic changes
with degeneration of the media as a common denominator.
explanation: >-
The cardiovascular pathology consensus statement identifies vasculopathic
aging alongside genetic syndromes as an upstream cause converging on
medial degeneration.
- reference: PMID:29360940
reference_title: "From genetics to response to injury: vascular smooth muscle cells in aneurysms and dissections of the ascending aorta."
supports: SUPPORT
evidence_source: OTHER
snippet: "degenerative form linked to the aortic aging process"
explanation: >-
Names the aging-linked degenerative form as one of the predominant
aetiologies of thoracic aortic aneurysm and dissection. Evidence source is
OTHER because this is a review synthesizing multiple study types.
- reference: PMID:39145396
reference_title: "Acute Aortic Dissection: Observational Lessons Learned From 11 000 Patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Over time, the rates of hypertension increased from 77.8% to 80.4%"
explanation: >-
In the IRAD registry of acute aortic dissections, roughly four in five
patients were hypertensive, supporting chronic pressure loading as a
dominant acquired risk factor.
downstream:
- target: Medial degeneration of the aortic wall
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Bicuspid aortic valve-associated altered wall shear stress
description: >-
A bicuspid aortic valve produces an eccentric, high-velocity systolic jet
that imposes regionally elevated wall shear stress (WSS) on the ascending
aortic convexity. Elevated WSS is associated with locally altered aortic
wall biomechanics and maladaptive remodeling, giving a hemodynamic route to
ascending aneurysm that is distinct from, and additive to, the intrinsic
vascular smooth muscle cell abnormality also documented in bicuspid aortic
tissue.
role: trigger
biological_scale: TISSUE
cell_types:
- preferred_term: endothelial cell
term:
id: CL:0000115
label: endothelial cell
evidence:
- reference: PMID:36797175
reference_title: "Magnetic resonance imaging-based hemodynamic wall shear stress alters aortic wall tissue biomechanics in bicuspid aortic valve patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Elevated WSS in the ascending aorta of patients with bicuspid aortic valve
has been shown to contribute to local maladaptive aortic remodeling and
might alter biomechanics.
explanation: >-
States the hemodynamic premise linking bicuspid-valve-driven elevated wall
shear stress to maladaptive ascending aortic remodeling.
- reference: PMID:36797175
reference_title: "Magnetic resonance imaging-based hemodynamic wall shear stress alters aortic wall tissue biomechanics in bicuspid aortic valve patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
This study shows strong evidence that biomechanical changes in the aorta
are strongly associated with hemodynamics
explanation: >-
Biaxial testing of resected bicuspid aortopathy tissue mapped to 4D-flow
MRI confirms that regional hemodynamics, not sampling region, tracks with
altered wall biomechanics.
downstream:
- target: Vascular smooth muscle cell depletion
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- target: Medial degeneration of the aortic wall
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Vascular smooth muscle cell depletion
description: >-
Loss of medial vascular smooth muscle cells (VSMCs) by apoptosis and
phenotypic failure removes the cells responsible for maintaining and
repairing the elastic lamellar units. In resected ascending aneurysm tissue
VSMCs show both defective secretion of matrix proteins and a several-fold
increase in apoptotic loss, with MMP-2 upregulation implicated in driving
that loss.
role: effector
biological_scale: CELLULAR
cell_types:
- preferred_term: vascular associated smooth muscle cell
term:
id: CL:0000359
label: vascular associated smooth muscle cell
biological_processes:
- preferred_term: apoptotic process
modifier: INCREASED
term:
id: GO:0006915
label: apoptotic process
evidence:
- reference: PMID:12970255
reference_title: "Abnormal extracellular matrix protein transport associated with increased apoptosis of vascular smooth muscle cells in marfan syndrome and bicuspid aortic valve thoracic aortic aneurysm."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
In MS and BAV there is alteration in both the amount and quality of
secreted proteins and an increased degree of VSMC apoptosis.
explanation: >-
Cultured VSMCs from resected Marfan and bicuspid-valve thoracic aneurysm
tissue show both defective matrix protein secretion and increased
apoptosis.
- reference: PMID:12970255
reference_title: "Abnormal extracellular matrix protein transport associated with increased apoptosis of vascular smooth muscle cells in marfan syndrome and bicuspid aortic valve thoracic aortic aneurysm."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
Immunohistochemical study of cultured MS and BAV VSMC showed intracellular
accumulation and reduction of extracellular distribution of fibrillin,
fibronectin, and tenascin.
explanation: >-
Documents the secretory defect — matrix proteins retained intracellularly
rather than deposited into the media — underlying the VSMC contribution.
- reference: PMID:29360940
reference_title: "From genetics to response to injury: vascular smooth muscle cells in aneurysms and dissections of the ascending aorta."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
vSMC disappearance, medial areas of mucoid degeneration, and extracellular
matrix (ECM) breakdown
explanation: >-
Names VSMC disappearance as one of the defining histopathological
alterations of thoracic aortic aneurysm and dissection. Evidence source is
OTHER because this is a review.
downstream:
- target: Medial degeneration of the aortic wall
causal_link_type: DIRECT
- name: Extracellular matrix proteolysis and elastic fiber fragmentation
description: >-
Protease-mediated destruction of the medial extracellular matrix —
matrix metalloproteinase activity, plus plasmin generated from plasminogen
that is convected across the abnormally permeable aortic wall — degrades
elastin and fibrillar collagen. Loss of intact elastic lamellae removes the
principal load-bearing element of the media. Inflammatory reactions and
oxidative stress act as amplifiers of this proteolytic injury rather than as
the primary lesion, distinguishing thoracic medial degeneration from the
florid transmural inflammation of abdominal aortic aneurysm.
role: effector
biological_scale: MOLECULAR
biological_processes:
- preferred_term: extracellular matrix disassembly
modifier: INCREASED
term:
id: GO:0022617
label: extracellular matrix disassembly
notes: >-
GO:0048251 elastic fiber assembly (DECREASED) was removed from this node
during review. The claim here is proteolytic DESTRUCTION of existing
elastin, which GO:0022617 extracellular matrix disassembly (INCREASED)
already states; reduced assembly is a different mechanism, is not what the
cited evidence shows, and carrying both would have implied a synthetic
defect the sources do not support.
evidence:
- reference: PMID:12970255
reference_title: "Abnormal extracellular matrix protein transport associated with increased apoptosis of vascular smooth muscle cells in marfan syndrome and bicuspid aortic valve thoracic aortic aneurysm."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "Up-regulation of MMP-2 might play a role in VSMC apoptosis in MS VSMC."
explanation: >-
Implicates MMP-2 upregulation, a matrix-degrading protease, in the
cellular injury of thoracic aneurysm tissue.
- reference: PMID:29360940
reference_title: "From genetics to response to injury: vascular smooth muscle cells in aneurysms and dissections of the ascending aorta."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
aneurysms and dissections, whatever their aetiologies, are characterized by
an increase in wall permeability leading to transmural advection of plasma
proteins which could interact with vSMCs and ECM components
explanation: >-
Describes the aetiology-independent wall-permeability/plasminogen route to
proteolytic matrix injury. Evidence source is OTHER because this is a
review.
- reference: PMID:23856125
reference_title: "Molecular mechanisms of thoracic aortic dissection."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Inflammatory reactions and increased oxidative stress are cellular
responses to aortic injury, and they may induce protease-mediated
destruction of the aortic wall.
explanation: >-
Positions inflammation and oxidative stress as responses to aortic injury
that amplify protease-mediated wall destruction. Evidence source is OTHER
because this is a review.
downstream:
- target: Medial degeneration of the aortic wall
causal_link_type: DIRECT
- name: Segment-specific smooth muscle lineage susceptibility
description: >-
The thoracic aorta is a mosaic of vascular smooth muscle cells of different
embryonic origin: root VSMCs derive from cardiogenic mesoderm, the ascending
aorta from both cardiogenic mesoderm and cardiac neural crest, and the
descending thoracic aorta from somites. Lineages differ in their
transcriptional response to stimuli such as TGF-beta, and the boundaries
between them are proposed focal points of lamellar weakness. This
developmental mosaicism is a mechanistic explanation for why proximal and
distal thoracic aneurysm/dissection differ in age at onset, risk-factor
profile, and histology.
role: modifier
biological_scale: CELLULAR
cell_types:
- preferred_term: vascular associated smooth muscle cell
term:
id: CL:0000359
label: vascular associated smooth muscle cell
biological_processes:
- preferred_term: transforming growth factor beta receptor signaling pathway
term:
id: GO:0007179
label: transforming growth factor beta receptor signaling pathway
evidence:
- reference: PMID:23856125
reference_title: "Molecular mechanisms of thoracic aortic dissection."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
VSMCs in the root arise from cardiogenic mesoderm cells, whereas the
ascending aorta is composed of both cardiogenic mesodermal cells and
cardiac neural crest cells
explanation: >-
Establishes the differing embryonic origins of VSMCs across proximal
thoracic aortic segments. Evidence source is OTHER because this is a
review.
- reference: PMID:23856125
reference_title: "Molecular mechanisms of thoracic aortic dissection."
supports: SUPPORT
evidence_source: OTHER
snippet: "The descending thoracic aorta is composed of somite-derived SMCs"
explanation: >-
Confirms the distinct somitic origin of descending thoracic aortic VSMCs.
Evidence source is OTHER because this is a review.
- reference: PMID:23856125
reference_title: "Molecular mechanisms of thoracic aortic dissection."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
The transition points between different VSMCs may represent focal points of
weakness between lamellar units where dissection occurs or propagates.
explanation: >-
Proposes lineage-boundary weakness as the link from developmental
mosaicism to segment-specific dissection. Marked PARTIAL because the
source frames this as a hypothesis ("may represent"), not a demonstrated
mechanism.
- reference: PMID:23856125
reference_title: "Molecular mechanisms of thoracic aortic dissection."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Ascending TAD usually occurs in younger patients than descending TAD does
and is more often associated with a connective tissue disorder.
explanation: >-
Documents the clinical segment split that the lineage model is invoked to
explain. Evidence source is OTHER because this is a review.
- reference: PMID:23856125
reference_title: "Molecular mechanisms of thoracic aortic dissection."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
dissection arising in the descending thoracic aorta tends to occur in older
patients, who often have a history of hypertension
explanation: >-
Documents the older, hypertensive phenotype of descending thoracic
disease, the distal half of the segment split. Evidence source is OTHER
because this is a review.
- reference: PMID:34238012
reference_title: "Root Dilatation Is More Malignant Than Ascending Aortic Dilation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
studies of natural behavior have generally treated the aortic root and the
ascending aorta as 1 unit despite embryological, anatomical, and functional
differences
explanation: >-
Independently invokes embryological difference between root and ascending
aorta as the rationale for treating them as distinct segments, and the
study then confirms their natural histories differ.
- reference: PMID:34238012
reference_title: "Root Dilatation Is More Malignant Than Ascending Aortic Dilation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The natural histories of the aortic root and mid-ascending aorta are
uniquely different.
explanation: >-
Clinical confirmation that segment identity, not just diameter, governs
behaviour — the outcome the lineage-mosaicism model predicts.
downstream:
- target: Medial degeneration of the aortic wall
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- name: Medial degeneration of the aortic wall
description: >-
The convergent tissue lesion of thoracic aortic aneurysm: loss of smooth
muscle cell nuclei, fragmentation and/or loss of elastic fibers, and mucoid
extracellular matrix accumulation (MEMA) within the media. The 2016
Society for Cardiovascular Pathology / Association for European
Cardiovascular Pathology consensus replaced the older terms "cystic medial
necrosis" and "medionecrosis" with these descriptive terms and defined a
grading system. Importantly, this is a non-inflammatory degenerative lesion;
florid inflammatory infiltrate is characteristically absent.
role: central_effector
biological_scale: TISSUE
conforms_to: "aortopathy_tgfbeta_dysregulation#Aortic Medial Degeneration and Wall Weakening"
cell_types:
- preferred_term: vascular associated smooth muscle cell
term:
id: CL:0000359
label: vascular associated smooth muscle cell
biological_processes:
- preferred_term: extracellular matrix disassembly
modifier: INCREASED
term:
id: GO:0022617
label: extracellular matrix disassembly
evidence:
- reference: PMID:27031798
reference_title: "Consensus statement on surgical pathology of the aorta from the Society for Cardiovascular Pathology and the Association For European Cardiovascular Pathology: II. Noninflammatory degenerative diseases - nomenclature and diagnostic criteria."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Older terms such as cystic medial necrosis and medionecrosis are replaced
by more technically accurate terms such as mucoid extracellular matrix
accumulation (MEMA), elastic fiber fragmentation and/or loss, and smooth
muscle cell nuclei loss.
explanation: >-
Defines the three component lesions of medial degeneration in the current
consensus nomenclature for surgical aortic specimens.
- reference: PMID:23856125
reference_title: "Molecular mechanisms of thoracic aortic dissection."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Most cases of TAD are characterized by medial degeneration in the aortic
wall. This medial degeneration is associated with the fragmentation and
loss of elastic fibers, SMC depletion, fibrotic remodeling, and the
accumulation of mucopolysaccharides in the aortic media.
explanation: >-
Independently confirms medial degeneration as the dominant wall lesion and
enumerates its components. Evidence source is OTHER because this is a
review.
- reference: PMID:12970255
reference_title: "Abnormal extracellular matrix protein transport associated with increased apoptosis of vascular smooth muscle cells in marfan syndrome and bicuspid aortic valve thoracic aortic aneurysm."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
MS and BAV aneurysm histology showed areas of cystic medial necrosis (CMN)
without inflammatory infiltrate.
explanation: >-
Human aneurysm histology confirms the non-inflammatory character of the
medial lesion, distinguishing it from inflammation-driven abdominal
aneurysm.
downstream:
- target: Loss of wall tensile strength and progressive dilatation
causal_link_type: DIRECT
- name: Loss of wall tensile strength and progressive dilatation
description: >-
The degenerated media can no longer withstand the circumferential wall
stress imposed by pulsatile blood pressure. By the Laplace relationship,
each increment of dilatation raises wall tension, which drives further
dilatation — a self-reinforcing cycle. Growth is slow and accelerates with
size: the aneurysmal thoracic aorta enlarges by about 0.10 cm/year overall,
but far faster distally (0.19 cm/year descending) than proximally
(0.07 cm/year ascending). Because absolute diameter under-rates risk in
small patients, size indexed to height (aortic height index) or body surface
area (aortic size index) improves risk stratification.
role: effector
biological_scale: TISSUE
conforms_to: "aortopathy_tgfbeta_dysregulation#Progressive Aortic Dilation and Aneurysm"
evidence:
- reference: PMID:12440685
reference_title: "Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
the aneurysmal thoracic aorta grows at an average rate of 0.10 cm per year
(0.07 for ascending and 0.19 for descending)
explanation: >-
Quantifies the slow, segment-dependent growth of the dilating thoracic
aorta in the Yale natural-history cohort.
- reference: PMID:31982126
reference_title: "Natural history of descending thoracic and thoracoabdominal aortic aneurysms."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Estimated mean growth rate of descending thoracic and thoracoabdominal
aortic aneurysms was 0.19 cm/year, increasing with increasing aortic size.
explanation: >-
Confirms the descending growth rate and, critically, that growth
accelerates with size — the signature of the self-reinforcing Laplace
cycle.
- reference: PMID:29395211
reference_title: "Height alone, rather than body surface area, suffices for risk estimation in ascending aortic aneurysm."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Both ASI and AHI were shown to be significant predictors of complications"
explanation: >-
Establishes that body-size-indexed aortic dimensions predict natural
complications, motivating index-based rather than purely diameter-based
risk assessment.
- reference: PMID:29395211
reference_title: "Height alone, rather than body surface area, suffices for risk estimation in ascending aortic aneurysm."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
the simpler height-based ratio (excluding weight and BSA calculations)
yields satisfactory results for evaluating the risk of natural
complications
explanation: >-
Supports the aortic height index as a practical body-size adjustment for
risk estimation in ascending aneurysm.
downstream:
- target: Aortic dissection and rupture
causal_link_type: DIRECT
- name: Aortic dissection and rupture
description: >-
Wall failure, the lethal endpoint. When stress exceeds the strength of the
degenerated media, an intimal tear admits blood into the media and propagates
a dissection, or the wall ruptures outright. Rupture risk is strongly
non-linear in diameter: hinge points for natural complications occur near
6.0 cm for the ascending and 7.0 cm for the descending aorta, and a 6 cm
aorta carries an approximately 14% annual risk of rupture, dissection, or
death. Dissection, however, does NOT follow the same size dependence — a
majority of both type A (59% below 5.5 cm) and type B (80% below 5 cm)
dissections occur below the operative threshold, so diameter-triggered
prophylactic repair prevents rupture far more effectively than it prevents
dissection.
role: consequence
biological_scale: ORGANISM
conforms_to: "aortopathy_tgfbeta_dysregulation#Aortic Dissection and Rupture"
evidence:
- reference: PMID:12440685
reference_title: "Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
hinge points for natural complications of aortic aneurysm (rupture or
dissection) were found at 6.0 cm for the ascending aorta and 7.0 cm for the
descending
explanation: >-
Establishes the non-linear, size-dependent hinge points at which
catastrophic complications sharply increase.
- reference: PMID:12440685
reference_title: "Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
a patient with an aorta that has reached 6 cm maximal diameter faces the
following yearly rates of devastating adverse events: rupture (3.6%),
dissection (3.7%), death (10.8%), rupture, dissection, or death (14.1%)
explanation: >-
Quantifies the annual event rates at the 6 cm hinge point that justify
preemptive repair.
- reference: PMID:31982126
reference_title: "Natural history of descending thoracic and thoracoabdominal aortic aneurysms."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Median size at acute type B dissection was 4.1 cm. Some 80% of dissections
occurred below 5 cm, whereas 93% of ruptures occurred above 5 cm.
explanation: >-
Demonstrates the divergent size dependence of dissection versus rupture in
the descending aorta — the basis for the caveat that size-based surgery
does not protect against dissection.
- reference: PMID:17709637
reference_title: "Aortic diameter >or = 5.5 cm is not a good predictor of type A aortic dissection: observations from the International Registry of Acute Aortic Dissection (IRAD)."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Maximum aortic diameters averaged 5.3 cm; 349 (59%) patients had aortic
diameters <5.5 cm and 229 (40%) patients had aortic diameters <5.0 cm.
explanation: >-
Extends the sub-threshold dissection finding to the ascending aorta: most
type A dissections in IRAD occurred below the 5.5 cm operative threshold.
- reference: PMID:9851478
reference_title: "Improved prognosis of thoracic aortic aneurysms: a population-based study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The 5-year risk of rupture as a function of aneurysm size at recognition
was 0% for aneurysms less than 4 cm in diameter
explanation: >-
Independent population-based confirmation of the steep size-dependence of
rupture risk, outside a surgical referral cohort; the same sentence reports
16% for 4-5.9 cm and 31% for 6 cm or more.
phenotypes:
- category: Cardiovascular
name: Thoracic aortic aneurysm
description: >-
Localized permanent dilatation of the thoracic aorta, the defining lesion.
Usually asymptomatic and discovered incidentally on imaging performed for
another indication.
phenotype_term:
preferred_term: Thoracic aortic aneurysm
term:
id: HP:0012727
label: Thoracic aortic aneurysm
clinical_course: PROGRESSIVE
frequency: VERY_FREQUENT
evidence:
- reference: PMID:9851478
reference_title: "Improved prognosis of thoracic aortic aneurysms: a population-based study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Managing thoracic aortic aneurysms identified incidentally by increased use
of computed tomography, echocardiography, and magnetic resonance imaging is
problematic, especially in the elderly.
explanation: >-
Confirms that thoracic aortic aneurysm is characteristically an incidental,
asymptomatic imaging finding. Frequency is VERY_FREQUENT because the
dilatation is the disease-defining lesion, present in all cases by
definition.
- category: Cardiovascular
name: Aortic dissection
description: >-
Separation of the layers of the aortic wall by blood entering the media
through an intimal tear. Dissection characteristically occurs at modest
diameters in both segments — median 4.1 cm for type B, and 59% of type A
dissections below 5.5 cm — so it is not reliably prevented by diameter-based
prophylactic repair.
phenotype_term:
preferred_term: Aortic dissection
term:
id: HP:0002647
label: Aortic dissection
temporality: ACUTE
evidence:
- reference: PMID:12440685
reference_title: "Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
a patient with an aorta that has reached 6 cm maximal diameter faces the
following yearly rates of devastating adverse events: rupture (3.6%),
dissection (3.7%), death (10.8%), rupture, dissection, or death (14.1%)
explanation: >-
Documents dissection as a quantified natural complication of thoracic
aortic aneurysm.
- reference: PMID:31982126
reference_title: "Natural history of descending thoracic and thoracoabdominal aortic aneurysms."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Median size at acute type B dissection was 4.1 cm."
explanation: >-
Establishes the characteristically modest aortic size at which descending
(type B) dissection occurs.
- reference: PMID:17709637
reference_title: "Aortic diameter >or = 5.5 cm is not a good predictor of type A aortic dissection: observations from the International Registry of Acute Aortic Dissection (IRAD)."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The majority of patients with acute type A acute aortic dissection present
with aortic diameters <5.5 cm and thus do not fall within current
guidelines for elective aneurysm surgery.
explanation: >-
IRAD registry evidence that most type A dissections occur below the
elective-surgery diameter threshold.
- category: Cardiovascular
name: Aortic rupture
description: >-
Frank transmural failure of the aortic wall with catastrophic hemorrhage.
Unlike dissection, rupture risk rises steeply with diameter, and in the
descending aorta more than 90% of ruptures occur above 5 cm.
phenotype_term:
preferred_term: Aortic rupture
term:
id: HP:0031649
label: Aortic rupture
temporality: ACUTE
evidence:
- reference: PMID:9851478
reference_title: "Improved prognosis of thoracic aortic aneurysms: a population-based study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The cumulative risk of rupture was 20% after 5 years. Seventy-nine percent
of ruptures occurred in women
explanation: >-
Quantifies the cumulative 5-year rupture risk in a population-based cohort
of degenerative thoracic aortic aneurysm.
- reference: PMID:31982126
reference_title: "Natural history of descending thoracic and thoracoabdominal aortic aneurysms."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "93% of ruptures occurred above 5 cm"
explanation: >-
Establishes the strong size threshold for rupture in the descending
thoracic aorta.
- category: Cardiovascular
name: Aortic root aneurysm
description: >-
Dilatation localized to the aortic root (sinuses of Valsalva). The root is
not simply the proximal end of the ascending aorta: it has a distinct
natural history, and root dilatation carries a higher risk of adverse events
than mid-ascending dilatation of the same degree, with a lower hinge point
(5.0 cm versus 5.25 cm). Root involvement is also the segment most enriched
for heritable aortopathy.
phenotype_term:
preferred_term: Aortic root aneurysm
term:
id: HP:0002616
label: Aortic root aneurysm
evidence:
- reference: PMID:34238012
reference_title: "Root Dilatation Is More Malignant Than Ascending Aortic Dilation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Dilation of the aortic root imparts a significant higher risk of adverse events."
explanation: >-
Yale cohort of 1,162 patients with ascending thoracic aortic aneurysm, in
which root and mid-ascending diameters were measured separately, showing
that root dilatation is the more dangerous of the two.
- reference: PMID:34238012
reference_title: "Root Dilatation Is More Malignant Than Ascending Aortic Dilation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The dedicated risk curves for the aortic root and the mid-ascending aorta
revealed hinge points at 5.0 and 5.25 cm, respectively.
explanation: >-
Quantifies the segment-specific hinge points that distinguish root from
mid-ascending aneurysm.
- reference: PMID:23856125
reference_title: "Molecular mechanisms of thoracic aortic dissection."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Ascending TAD usually occurs in younger patients than descending TAD does
and is more often associated with a connective tissue disorder.
explanation: >-
Supports the proximal segment as the one enriched for younger patients and
heritable connective tissue disease. Marked PARTIAL because the source
addresses the ascending aorta as a whole and does not separate the root.
Evidence source is OTHER because this is a review.
- category: Cardiovascular
name: Bicuspid aortic valve
description: >-
A congenital two-cusp aortic valve that generates an eccentric high-shear jet
against the ascending aorta and is a major risk factor for ascending
aneurysm. Bicuspid aortic tissue also shows an intrinsic vascular smooth
muscle cell abnormality independent of the valve hemodynamics.
phenotype_term:
preferred_term: Bicuspid aortic valve
term:
id: HP:0001647
label: Bicuspid aortic valve
evidence:
- reference: PMID:36797175
reference_title: "Magnetic resonance imaging-based hemodynamic wall shear stress alters aortic wall tissue biomechanics in bicuspid aortic valve patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Preoperative 4-dimensional flow magnetic resonance imaging was performed on
22 patients who underwent prophylactic aortic root and/or ascending aorta
replacement.
explanation: >-
A surgical cohort of bicuspid aortopathy patients requiring prophylactic
root/ascending replacement, directly evidencing the co-occurrence of
bicuspid aortic valve with operative-threshold ascending aneurysm.
- reference: PMID:12970255
reference_title: "Abnormal extracellular matrix protein transport associated with increased apoptosis of vascular smooth muscle cells in marfan syndrome and bicuspid aortic valve thoracic aortic aneurysm."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
Bicuspid aortic valve (BAV) is a congenital heart malformation of unknown
cause. Both conditions are associated with ascending aortic aneurysm and
premature death.
explanation: >-
States the bicuspid-valve/ascending-aneurysm association. Marked PARTIAL
because this sentence is background framing in an in vitro study rather
than a finding the study itself establishes.
- reference: PMID:12970255
reference_title: "Abnormal extracellular matrix protein transport associated with increased apoptosis of vascular smooth muscle cells in marfan syndrome and bicuspid aortic valve thoracic aortic aneurysm."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
The findings suggest the presence of a fundamental cellular abnormality in
BAV thoracic aorta, possibly of genetic origin.
explanation: >-
Supports an intrinsic cellular (not purely hemodynamic) contribution of
bicuspid aortopathy to aneurysm formation.
- category: Cardiovascular
name: Ascending aortic aneurysm
description: >-
Aneurysm of the tubular ascending aorta, the commonest thoracic segment
involved and the one with the slower growth rate of the two major segments -
0.07 cm/year against 0.19 for the descending aorta. Its hinge point for
rupture or dissection sits at 6.0 cm, a full centimetre below the descending
threshold, which is why segment identity rather than absolute diameter drives
the intervention decision. Distinguished from aortic root aneurysm, curated
separately here, because the root has its own natural history.
phenotype_term:
preferred_term: Ascending tubular aorta aneurysm
term:
id: HP:0004970
label: Ascending tubular aorta aneurysm
evidence:
- reference: PMID:12440685
reference_title: "Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
hinge points for natural complications of aortic aneurysm (rupture or
dissection) were found at 6.0 cm for the ascending aorta and 7.0 cm for the
descending.
explanation: >-
Establishes the ascending segment as a distinct entity with its own
complication threshold, which is the clinical expression of the
segment-specific susceptibility this entry models mechanistically.
- reference: PMID:12440685
reference_title: "Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
the aneurysmal thoracic aorta grows at an average rate of 0.10 cm per year
(0.07 for ascending and 0.19 for descending).
explanation: >-
The segment-specific growth rates, nearly threefold different, from the
same 1600-patient prospective series.
- category: Cardiovascular
name: Descending thoracic aortic aneurysm
description: >-
Aneurysm of the descending thoracic aorta, which grows almost three times
faster than the ascending segment (0.19 versus 0.07 cm/year) yet tolerates a
larger diameter before its complication hinge point at 7.0 cm. A caveat worth
carrying: the median size at acute type B dissection was 4.1 cm, well below
that hinge point, so a diameter-based rule does not capture dissection risk in
this segment the way it captures rupture risk.
phenotype_term:
preferred_term: Descending thoracic aorta aneurysm
term:
id: HP:0004959
label: Descending thoracic aorta aneurysm
evidence:
- reference: PMID:31982126
reference_title: "Natural history of descending thoracic and thoracoabdominal aortic aneurysms."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Estimated mean growth rate of descending thoracic and thoracoabdominal
aortic aneurysms was 0.19 cm/year, increasing with increasing aortic size.
explanation: >-
Independent confirmation of the descending growth rate in a dedicated
907-patient series, with the additional observation that growth accelerates
with size.
- reference: PMID:31982126
reference_title: "Natural history of descending thoracic and thoracoabdominal aortic aneurysms."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Median size at acute type B dissection was 4.1 cm.
explanation: >-
The datum that complicates diameter-based management of this segment:
dissection typically occurred well below the 7.0 cm hinge point (and below the 6.5 cm diameter at which
intervention is recommended for this segment).
- category: Cardiovascular
name: Chest pain
description: >-
The principal symptom, and one whose absence is more characteristic than its
presence - thoracic aortic aneurysm is usually silent until complication, so
new or severe chest or back pain in a known aneurysm is treated as
dissection until proven otherwise rather than as a stable symptom.
phenotype_term:
preferred_term: Chest pain
term:
id: HP:0100749
label: Chest pain
notes: >-
Deliberately carries no evidence item and no frequency. No cached source for
this entry quantifies symptom frequency in unruptured thoracic aortic
aneurysm, and the clinical rule stated here is guideline practice rather than
a finding of any cited study. Curated because a phenotype list containing
only imaging findings would misrepresent how this disease presents.
- category: Cardiovascular
name: Death from aortic complication
description: >-
Mortality is the terminal outcome the entire size-threshold literature exists
to prevent, and until now the pathograph in this entry stopped at dissection
and rupture without representing it. At 6 cm maximal diameter the yearly rate
of death reaches 10.8%, exceeding the rates of rupture and dissection
individually - which is the quantitative core of the argument for elective
repair before that diameter.
phenotype_term:
preferred_term: Sudden death
term:
id: HP:0001699
label: Sudden death
evidence:
- reference: PMID:12440685
reference_title: "Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
a patient with an aorta that has reached 6 cm maximal diameter faces the
following yearly rates of devastating adverse events: rupture (3.6%),
dissection (3.7%), death (10.8%), rupture, dissection, or death (14.1%).
explanation: >-
Quantifies death as a distinct outcome alongside rupture and dissection,
and at a higher yearly rate than either.
notes: >-
HP:0001699 Sudden death is the closest available term. The 10.8% yearly
figure is all-cause death in this aneurysm cohort rather than specifically
sudden death, so the term is broader in mechanism than the cited datum;
preferred_term keeps the phenotype label general for that reason.
- category: Cardiovascular
name: Aortic regurgitation
description: >-
Valve incompetence arising from the aneurysm itself rather than from primary
valve disease: root dilatation widens the aortic annulus and separates the
commissures, so the leaflets no longer coapt. This is the structural
consequence that makes root aneurysms behave differently from tubular ones,
and it is the main reason roots are operated at smaller diameters - the
decision is driven by valve competence as well as by rupture risk. It also
changes the operation: a competent-leaflet root can take a valve-sparing
replacement, whereas established regurgitation with damaged leaflets points
to a composite graft.
phenotype_term:
preferred_term: Aortic regurgitation
term:
id: HP:0001659
label: Aortic regurgitation
frequency: FREQUENT
evidence:
- reference: PMID:10685714
reference_title: "The International Registry of Acute Aortic Dissection (IRAD): new insights into an old disease."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Classic physical findings such as aortic regurgitation and pulse deficit
were noted in only 31.6% and 15.1% of patients, respectively
explanation: >-
Quantifies aortic regurgitation in a large registry, and the word "only"
is the authors' point: it is present in under a third even where it is
classically expected. PARTIAL, and the caveat is important - this is the
acute DISSECTION population, not the stable aneurysm population this entry
otherwise describes, so the figure bounds rather than measures the
frequency in unruptured disease. The FREQUENT band is set from this
figure and should be read with that ascertainment attached.
notes: >-
Curated after a previous round declined it for want of a cached source. The
mechanistic case is what justifies it independently of the frequency: root
dilatation to annular dilatation to valve incompetence is a direct
structural consequence of the Loss of wall tensile strength and progressive
dilatation node this entry already models, and without it the pathograph's
downstream story runs only to dissection and rupture, omitting the
commonest reason a root aneurysm is repaired early.
histopathology:
- name: Medial degeneration (MEMA, elastic fiber fragmentation, smooth muscle cell nuclei loss)
description: >-
The diagnostic surgical-pathology lesion of resected thoracic aortic
aneurysm. The 2016 SCVP/AECVP consensus retired "cystic medial necrosis" and
"medionecrosis" in favor of three separately graded descriptive findings:
mucoid extracellular matrix accumulation (MEMA), elastic fiber fragmentation
and/or loss, and smooth muscle cell nuclei loss. Inflammatory infiltrate is
characteristically absent — this is a non-inflammatory degenerative lesion.
evidence:
- reference: PMID:27031798
reference_title: "Consensus statement on surgical pathology of the aorta from the Society for Cardiovascular Pathology and the Association For European Cardiovascular Pathology: II. Noninflammatory degenerative diseases - nomenclature and diagnostic criteria."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Older terms such as cystic medial necrosis and medionecrosis are replaced
by more technically accurate terms such as mucoid extracellular matrix
accumulation (MEMA), elastic fiber fragmentation and/or loss, and smooth
muscle cell nuclei loss.
explanation: >-
Defines the current consensus histopathological nomenclature for the
medial lesion of thoracic aortic aneurysm.
- reference: PMID:27031798
reference_title: "Consensus statement on surgical pathology of the aorta from the Society for Cardiovascular Pathology and the Association For European Cardiovascular Pathology: II. Noninflammatory degenerative diseases - nomenclature and diagnostic criteria."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
A straightforward system of grading is presented to gauge the extent of
medial degeneration
explanation: >-
Confirms that the consensus provides a formal grading scheme for reporting
the extent of medial degeneration.
- reference: PMID:12970255
reference_title: "Abnormal extracellular matrix protein transport associated with increased apoptosis of vascular smooth muscle cells in marfan syndrome and bicuspid aortic valve thoracic aortic aneurysm."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
MS and BAV aneurysm histology showed areas of cystic medial necrosis (CMN)
without inflammatory infiltrate.
explanation: >-
Documents the absence of inflammatory infiltrate in human thoracic aneurysm
histology, the feature that separates it from abdominal aortic aneurysm.
environmental:
- name: Systemic hypertension
description: >-
Chronic elevation of blood pressure increases circumferential wall stress on
the thoracic aorta and is the leading modifiable risk factor for aneurysm
progression and dissection, particularly for descending thoracic disease in
older patients.
evidence:
- reference: PMID:39145396
reference_title: "Acute Aortic Dissection: Observational Lessons Learned From 11 000 Patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Over time, the rates of hypertension increased from 77.8% to 80.4%"
explanation: >-
Hypertension is present in roughly 80% of patients enrolled in the
International Registry of Acute Aortic Dissection. Note the denominator is
patients presenting with dissection, not an unselected aneurysm cohort, so
this is a risk-factor prevalence rather than a phenotype frequency.
- reference: PMID:17709637
reference_title: "Aortic diameter >or = 5.5 cm is not a good predictor of type A aortic dissection: observations from the International Registry of Acute Aortic Dissection (IRAD)."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Independent predictors of dissection at smaller diameters (<5.5 cm)
included a history of hypertension
explanation: >-
Hypertension is an independent predictor of dissection occurring below the
operative diameter threshold, strengthening its status as a causal risk
factor rather than an incidental association.
- reference: PMID:23856125
reference_title: "Molecular mechanisms of thoracic aortic dissection."
supports: SUPPORT
evidence_source: OTHER
snippet: >-
dissection arising in the descending thoracic aorta tends to occur in older
patients, who often have a history of hypertension
explanation: >-
Links hypertension specifically to the descending thoracic segment.
Evidence source is OTHER because this is a review.
- name: Aging
description: >-
Age-related vasculopathic change in the aortic media is the principal
non-modifiable driver of sporadic degenerative thoracic aortic aneurysm.
In the Olmsted County population-based cohort, women with thoracic aortic
aneurysm were recognized at a mean age of 75.9 years and men at 62.8 years.
evidence:
- reference: PMID:27031798
reference_title: "Consensus statement on surgical pathology of the aorta from the Society for Cardiovascular Pathology and the Association For European Cardiovascular Pathology: II. Noninflammatory degenerative diseases - nomenclature and diagnostic criteria."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
vasculopathic aging processes involved in vascular injury can cause both
distinct and nonspecific histopathologic changes with degeneration of the
media as a common denominator
explanation: >-
Identifies vasculopathic aging as a cause converging on medial
degeneration.
- reference: PMID:9851478
reference_title: "Improved prognosis of thoracic aortic aneurysms: a population-based study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
51% of thoracic aortic aneurysms were identified in women who were
considerably older at recognition than men (mean age, 75.9 vs 62.8 years,
respectively; P= .01)
explanation: >-
Documents the advanced age at recognition, and the notable sex difference,
in population-based degenerative thoracic aortic aneurysm.
- name: Fluoroquinolone exposure
description: >-
Systemic fluoroquinolone antibiotics are associated with a short-term
increase in the risk of aortic aneurysm or dissection, an association driven
largely by aneurysm rather than dissection. The absolute excess risk is small
(an estimated 82 extra cases per million treatment episodes by 60 days), but
the association underlies current advice to avoid fluoroquinolones in
patients with known aortic aneurysm or aortopathy risk.
evidence:
- reference: PMID:29519881
reference_title: "Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Fluoroquinolone use was associated with an increased risk of aortic
aneurysm or dissection (hazard ratio 1.66
explanation: >-
Propensity-matched Swedish nationwide cohort quantifying the
fluoroquinolone-associated risk increase; the source gives the 95%
confidence interval as 1.12 to 2.46.
- reference: PMID:29519881
reference_title: "Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In a propensity score matched cohort, fluoroquinolone use was associated
with an increased risk of aortic aneurysm or dissection. This association
appeared to be largely driven by aortic aneurysm.
explanation: >-
Qualifies the signal as driven mainly by aneurysm; marked PARTIAL because
this is an observational association from which causality cannot be
established.
- name: Cigarette smoking
exposure_term:
preferred_term: exposure to cigarette smoking
term:
id: ECTO:0100003
label: exposure to cigarette smoking
description: >-
Smoking is over-represented among individuals with thoracic aortic aneurysm
and dissection. Its contribution is less dominant here than in abdominal
aortic aneurysm, where smoking is the single strongest risk factor.
evidence:
- reference: PMID:37308786
reference_title: "Genome-wide association study of thoracic aortic aneurysm and dissection in the Million Veteran Program."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Participants with TAAD were more likely to be older, male, prescribed
statin therapy and former smokers.
explanation: >-
Baseline characteristics of TAAD cases in the Million Veteran Program show
enrichment for former smoking. Marked PARTIAL because this is an unadjusted
baseline-characteristics comparison, not a risk estimate.
genetic:
- name: Family history of arterial aneurysm
relationship_type: SUSCEPTIBILITY
notes: >-
A substantial minority of thoracic aortic aneurysm probands have affected
first-degree relatives, indicating that heritable aortopathy is
under-recognized within apparently sporadic thoracic aortic aneurysm
populations. This is the rationale for family screening and for referring
selected probands for genetic evaluation; the specific monogenic entities
are curated as separate dismech entries (see notes).
evidence:
- reference: PMID:12440685
reference_title: "Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
family pedigrees confirm that 21% of probands with thoracic aortic aneurysm
have first-order family members with arterial aneurysm
explanation: >-
Quantifies the familial clustering seen within an unselected thoracic
aortic aneurysm cohort.
- reference: PMID:12440685
reference_title: "Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Family members should be evaluated."
explanation: >-
States the resulting clinical recommendation for family evaluation.
diagnosis:
- name: Cross-sectional and echocardiographic aortic imaging
description: >-
Diagnosis rests on measuring aortic diameter by CT angiography, MR
angiography, or echocardiography. Most aneurysms are found incidentally on
imaging performed for another indication. Diameter should be interpreted
alongside a body-size index (aortic height index or aortic size index),
since absolute diameter under-rates risk in smaller patients.
evidence:
- reference: PMID:9851478
reference_title: "Improved prognosis of thoracic aortic aneurysms: a population-based study."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Managing thoracic aortic aneurysms identified incidentally by increased use
of computed tomography, echocardiography, and magnetic resonance imaging is
problematic, especially in the elderly.
explanation: >-
Names the three imaging modalities by which thoracic aortic aneurysm is
detected.
- reference: PMID:29395211
reference_title: "Height alone, rather than body surface area, suffices for risk estimation in ascending aortic aneurysm."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Both ASI and AHI were shown to be significant predictors of complications"
explanation: >-
Supports body-size-indexed aortic measurement as part of diagnostic risk
assessment.
treatments:
- name: Serial aortic imaging surveillance
description: >-
Repeated measurement of aortic diameter by CT, MR, or echocardiography to
detect progressive dilatation and time prophylactic repair before the
diameter hinge point is reached. Surveillance is the core management strategy
for aneurysms below the operative threshold, and long-term surveillance is a
named domain of the 2022 ACC/AHA aortic disease guideline.
treatment_term:
preferred_term: magnetic resonance imaging surveillance
term:
id: NCIT:C16809
label: Magnetic Resonance Imaging
evidence:
- reference: PMID:36334952
reference_title: "2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
provides recommendations to guide clinicians in the diagnosis, genetic
evaluation and family screening, medical therapy, endovascular and surgical
treatment, and long-term surveillance of patients with aortic disease
explanation: >-
The ACC/AHA guideline identifies long-term surveillance as a core
management domain for aortic disease.
- reference: PMID:12440685
reference_title: "Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
the aneurysmal thoracic aorta grows at an average rate of 0.10 cm per year
(0.07 for ascending and 0.19 for descending)
explanation: >-
The slow, measurable growth rate is what makes interval imaging
surveillance an effective strategy.
- name: Blood-pressure and wall-stress reducing pharmacotherapy
description: >-
Antihypertensive therapy, conventionally beta-blockade and/or
renin-angiotensin system blockade, to lower the pulsatile wall stress driving
dilatation. Medical therapy is a named management domain in the 2022 ACC/AHA
aortic disease guideline. The evidence base is weaker than that framing
suggests: the strongest randomized data come from syndromic (Marfan) cohorts,
where the head-to-head Pediatric Heart Network trial found losartan no better
than atenolol, and no comparable randomized evidence exists for sporadic
degenerative thoracic aortic aneurysm. The distinction between those two
findings matters and is easy to collapse: an individual-patient-data
meta-analysis of seven randomized trials in Marfan syndrome found that
allocation to an ARB approximately halved the annual rate of aortic root Z
score increase against control, with the effect particularly large in
fibrillin-1 variant carriers. So ARBs do work against control; what the
head-to-head trial showed is that they are not superior to an active
beta-blocker comparator. Both agents are curated here for that reason.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: beta-adrenergic antagonist
term:
id: NCIT:C29576
label: Beta-Adrenergic Antagonist
- preferred_term: angiotensin II receptor antagonist
term:
id: NCIT:C66930
label: Angiotensin II Receptor Antagonist
target_mechanisms:
- target: Loss of wall tensile strength and progressive dilatation
treatment_effect: MODULATES
evidence:
- reference: PMID:36049495
reference_title: "Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
During a median follow-up of 3 years, allocation to ARB approximately
halved the annual rate of change in the aortic root Z score
explanation: >-
Randomized individual-patient-data evidence across seven trials that
angiotensin receptor blockade slows aortic root dilatation against
control. This is the comparison the head-to-head losartan-versus-atenolol
trial did not make, and it is why an ARB agent is curated here rather than
beta blockade alone.
- reference: PMID:36049495
reference_title: "Angiotensin receptor blockers and β blockers in Marfan syndrome: an individual patient data meta-analysis of randomised trials."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Prespecified secondary subgroup analyses showed that the effects of ARB
were particularly large in those with pathogenic variants in fibrillin-1,
compared with those without such variants (heterogeneity p=0·0050)
explanation: >-
The effect concentrates in fibrillin-1 carriers, which is mechanistically
informative but also the reason this evidence is PARTIAL for the present
entry: it comes from syndromic Marfan cohorts, and transfer to sporadic
degenerative thoracic aortic aneurysm is not established.
- reference: PMID:36334952
reference_title: "2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
provides recommendations to guide clinicians in the diagnosis, genetic
evaluation and family screening, medical therapy, endovascular and surgical
treatment, and long-term surveillance of patients with aortic disease
explanation: >-
The guideline abstract establishes medical therapy as a recommended
management domain but does not itself quote a specific drug-class effect
size; marked PARTIAL because the snippet supports the domain, not a
quantified benefit.
- reference: PMID:25405392
reference_title: "Atenolol versus losartan in children and young adults with Marfan's syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Both slopes were significantly less than zero, indicating a decrease in the
aortic-root diameter relative to body-surface area with either treatment.
explanation: >-
Both wall-stress-reducing regimens slowed body-size-indexed root growth in
Marfan syndrome. Marked PARTIAL because the cohort is syndromic Marfan, not
sporadic degenerative thoracic aortic aneurysm, so the benefit is
extrapolated rather than directly demonstrated for this entry's population.
- reference: PMID:25405392
reference_title: "Atenolol versus losartan in children and young adults with Marfan's syndrome."
supports: REFUTE
evidence_source: HUMAN_CLINICAL
snippet: >-
Among children and young adults with Marfan's syndrome who were randomly
assigned to losartan or atenolol, we found no significant difference in the
rate of aortic-root dilatation between the two treatment groups over a
3-year period.
explanation: >-
Recorded as REFUTE against the specific claim that TGF-beta/AT1-directed
therapy (losartan) is superior to conventional beta-blockade — the
randomized trial found no difference.
- name: Prophylactic open surgical repair
description: >-
Elective open replacement of the aneurysmal segment before the diameter
hinge point is reached. Conventional thresholds are approximately 5.5 cm for
the ascending aorta and 6.5 cm for the descending aorta in non-syndromic
disease, with earlier intervention (5.0 cm ascending, 6.0 cm descending) for
Marfan syndrome or familial thoracic aortic aneurysm. A contemporary
surveillance cohort found a seven-fold rise in mortality at diameters
>=5.5 cm, supporting that threshold for rupture prevention — though it does
not address the sub-threshold dissection problem.
therapeutic_modality: SURGERY
treatment_term:
preferred_term: thoracic aortic aneurysm open repair
term:
id: NCIT:C158011
label: Thoracic Aortic Aneurysm Open Repair
target_mechanisms:
- target: Aortic dissection and rupture
treatment_effect: INHIBITS
evidence:
- reference: PMID:12440685
reference_title: "Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We recommend intervention for the ascending aorta at 5.5 cm and for the
descending aorta at 6.5 cm.
explanation: >-
States the diameter thresholds for prophylactic repair derived from the
Yale natural-history risk/benefit analysis.
- reference: PMID:41532501
reference_title: "Ascending Thoracic Aortic Aneurysms in a Veterans Affairs Health System: Longitudinal Outcomes and Risk Factors."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
ATAA all-cause mortality increases with diameter, with a 7-fold incidence
increase in aneurysms ≥5.5 cm.
explanation: >-
Contemporary surveillance cohort evidence supporting the 5.5 cm
prophylactic-repair threshold for ascending aneurysm.
- reference: PMID:41532501
reference_title: "Ascending Thoracic Aortic Aneurysms in a Veterans Affairs Health System: Longitudinal Outcomes and Risk Factors."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Our findings support the 5.5 cm threshold for prophylactic ATAA repair"
explanation: >-
Explicit contemporary endorsement of the operative threshold.
- reference: PMID:17709637
reference_title: "Aortic diameter >or = 5.5 cm is not a good predictor of type A aortic dissection: observations from the International Registry of Acute Aortic Dissection (IRAD)."
supports: REFUTE
evidence_source: HUMAN_CLINICAL
snippet: >-
The majority of patients with acute type A acute aortic dissection present
with aortic diameters <5.5 cm and thus do not fall within current
guidelines for elective aneurysm surgery.
explanation: >-
Recorded as REFUTE against the broader claim that diameter-triggered
prophylactic repair prevents acute aortic events generally: most type A
dissections occur in patients who never met the operative criterion.
- name: Thoracic endovascular aortic repair (TEVAR)
description: >-
Endovascular stent-graft exclusion of a descending thoracic aneurysm.
Relative to open repair, TEVAR lowers postoperative mortality and morbidity
and improves freedom from aortic-related death, but carries a higher
reintervention burden and, in meta-analysis, inferior long-term all-cause
survival — so the choice is a trade-off between perioperative safety and
durability rather than a uniform advantage.
therapeutic_modality: DEVICE
treatment_term:
preferred_term: endovascular aneurysm repair
term:
id: NCIT:C157839
label: Endovascular Aneurysm Repair
target_mechanisms:
- target: Aortic dissection and rupture
treatment_effect: INHIBITS
evidence:
- reference: PMID:39869368
reference_title: "Comparison of short-and long-term outcomes between endovascular and open repair for descending thoracic aortic aneurysm: a systematic review and meta-analysis."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
endovascular repair was associated with better freedom from aortic-related
survival, a lower risk for postoperative mortality and morbidity
explanation: >-
Meta-analysis of 49,972 patients supports the perioperative and
aortic-related-survival advantage of TEVAR for descending thoracic
aneurysm.
- reference: PMID:39869368
reference_title: "Comparison of short-and long-term outcomes between endovascular and open repair for descending thoracic aortic aneurysm: a systematic review and meta-analysis."
supports: REFUTE
evidence_source: HUMAN_CLINICAL
snippet: >-
Open repair yielded significantly better long-term all-cause survival and
freedom from aortic-related re-intervention than endovascular repair.
explanation: >-
Counterbalancing evidence from the same meta-analysis: TEVAR is not
uniformly superior, with worse long-term all-cause survival and more
reinterventions. Recorded as REFUTE against a claim of unqualified TEVAR
superiority.
discussions:
- discussion_id: gap_taa_nondiameter_dissection_prediction
kind: KNOWLEDGE_GAP
status: OPEN
prompt: >-
Can aortic dissection risk be predicted by anything other than maximal
diameter, given that a majority of both type A and type B dissections occur
below the operative size threshold?
attaches_to:
- pathophysiology#Aortic dissection and rupture
- pathophysiology#Loss of wall tensile strength and progressive dilatation
rationale: >-
Rupture and dissection have different size dependence, yet the entire
management algorithm is built on diameter. In the descending aorta, median
size at acute type B dissection was 4.1 cm with 80% of dissections below
5 cm, while 93% of ruptures occurred above 5 cm. In the ascending aorta, 59%
of IRAD type A dissections presented below 5.5 cm. Diameter-triggered
prophylactic repair therefore addresses rupture well but leaves dissection
risk largely unmitigated, and the authors of both cohorts state this
explicitly. No validated non-diameter predictor (biomechanical, imaging
biomarker, or circulating marker) is yet in routine clinical use, so the most
common acute presentation of thoracic aortic disease is currently not
preventable by the standard size-based algorithm.
proposed_experiments:
- experiment_id: taa_nondiameter_dissection_predictors
name: Prospective imaging-biomarker cohort for sub-threshold aortic dissection
description: >-
Enrol patients under surveillance for thoracic aortic aneurysm below the
operative diameter threshold and collect 4D-flow MRI wall shear stress,
wall-strain/distensibility imaging, and aortic height index at baseline and
at intervals, with acute aortic dissection as the prespecified endpoint.
decision_criterion: >-
A candidate marker predicts dissection independently of maximal diameter in
multivariable competing-risks analysis, with reproducible discrimination in
an external validation cohort.
would_support:
- pathophysiology#Aortic dissection and rupture
evidence:
- reference: PMID:31982126
reference_title: "Natural history of descending thoracic and thoracoabdominal aortic aneurysms."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Acute type B dissections occur frequently at small aortic sizes; thus,
prophylactic size-based surgery may not afford a means for dissection
protection.
explanation: >-
The source authors state the gap directly for the descending aorta:
size-based prophylactic surgery does not protect against dissection.
- reference: PMID:17709637
reference_title: "Aortic diameter >or = 5.5 cm is not a good predictor of type A aortic dissection: observations from the International Registry of Acute Aortic Dissection (IRAD)."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Methods other than size measurement of the ascending aorta are needed to
identify patients at risk for dissection.
explanation: >-
The IRAD authors state the same gap for the ascending aorta and explicitly
call for non-diameter risk-prediction methods.
- reference: PMID:34238012
reference_title: "Root Dilatation Is More Malignant Than Ascending Aortic Dilation."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
the guideline criterion of 5.5 cm for ascending aortic intervention misses
many dissections occurring at smaller dimensions
explanation: >-
Restates the gap and offers one partial mitigation short of a new
biomarker — segment-specific hinge points (5.0 cm root, 5.25 cm
mid-ascending) rather than a single ascending threshold. Marked PARTIAL
because refining the diameter criterion narrows but does not close the
sub-threshold dissection gap.
- discussion_id: mismatch_taa_tgfbeta_losartan_translation
kind: HUMAN_MODEL_MISMATCH
status: OPEN
prompt: >-
Does the TGF-beta-antagonism mechanism that prevents aortic aneurysm in the
Marfan mouse translate into a clinically distinguishable benefit in humans,
and does it apply at all to sporadic degenerative thoracic aortic aneurysm?
attaches_to:
- pathophysiology#Loss of wall tensile strength and progressive dilatation
- pathophysiology#Segment-specific smooth muscle lineage susceptibility
rationale: >-
The mechanistic rationale for angiotensin-receptor blockade in aortopathy
comes from a fibrillin-1 mouse model, in which losartan and a
TGF-beta-neutralizing antibody prevented aneurysm outright. The subsequent
randomized human trial in Marfan syndrome found no difference between
losartan and atenolol in the rate of aortic-root dilatation over three years
— both slowed indexed growth, but the TGF-beta-directed agent conferred no
additional benefit than an active comparator. That trial is often read as
showing the mechanism failed to translate, and it does not show that: a
later individual-patient-data meta-analysis of seven randomized trials
(1442 patients) found ARB allocation approximately halved the annual rate of
aortic root Z score increase when compared against control rather than
against a beta blocker, with a significantly larger effect in fibrillin-1
variant carriers. The honest statement of the mismatch is therefore
narrower than "losartan did not work": ARBs demonstrably slow root dilatation
in Marfan syndrome, but they do not outperform beta blockade, so the
human data do not isolate a TGF-beta-specific benefit of the magnitude the
mouse model predicted. This remains a model-to-human fidelity question
rather than an absence of evidence. The gap is wider still for this entry, because even the human
trial evidence comes from syndromic Marfan disease, whereas sporadic
degenerative thoracic aortic aneurysm has no comparable randomized data and
is not established to be TGF-beta-driven at all. This is the main reason the
entry does not declare conformance to the
`aortopathy_tgfbeta_dysregulation#TGF-beta Signaling Dysregulation` node.
proposed_experiments:
- experiment_id: taa_tgfbeta_axis_in_sporadic_disease
name: TGF-beta pathway activity in sporadic versus syndromic thoracic aneurysm tissue
description: >-
Compare canonical TGF-beta pathway activation (phospho-SMAD2/3 signalling,
pathway transcriptional output) in resected aortic tissue from sporadic
degenerative thoracic aortic aneurysm, syndromic heritable aortopathy, and
non-aneurysmal control aorta, stratified by aortic segment and smooth
muscle lineage.
decision_criterion: >-
Sporadic degenerative aneurysm tissue shows TGF-beta pathway activation
comparable to syndromic aortopathy, versus control aorta, in independent
specimen series.
would_support:
- pathophysiology#Segment-specific smooth muscle lineage susceptibility
evidence:
- reference: PMID:16601194
reference_title: "Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome."
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: >-
We show that aortic aneurysm in a mouse model of MFS is associated with
increased TGF-beta signaling and can be prevented by TGF-beta antagonists
such as TGF-beta-neutralizing antibody or the angiotensin II type 1
receptor (AT1) blocker, losartan.
explanation: >-
The model-organism result establishing the TGF-beta antagonism rationale
that did not reproduce as a distinguishable clinical benefit in humans.
- reference: PMID:25405392
reference_title: "Atenolol versus losartan in children and young adults with Marfan's syndrome."
supports: REFUTE
evidence_source: HUMAN_CLINICAL
snippet: >-
Among children and young adults with Marfan's syndrome who were randomly
assigned to losartan or atenolol, we found no significant difference in the
rate of aortic-root dilatation between the two treatment groups over a
3-year period.
explanation: >-
The human randomized trial that did not reproduce a losartan-specific
advantage, defining the model-to-human mismatch.
notes: >-
**Scope.** This entry covers thoracic aortic aneurysm as the general clinical
entity, with emphasis on the sporadic degenerative form — the aging /
hypertension / bicuspid-valve disease that accounts for most clinically
recognized cases. It is the thoracic counterpart of the `Abdominal Aortic
Aneurysm` entry, and the two are mechanistically distinct: abdominal aneurysm
is driven by chronic transmural inflammation and MMP-mediated proteolysis,
whereas thoracic aneurysm is a characteristically NON-inflammatory medial
degeneration.
**Relationship to the heritable entries.** The monogenic and syndromic causes
of thoracic aortic disease are curated as their own dismech entries and are not
duplicated here: `Familial Thoracic Aortic Aneurysm and Aortic Dissection`
(nonsyndromic heritable, ACTA2/MYH11/MYLK/PRKG1 and related), `Marfan
Syndrome`, `Loeys-Dietz Syndrome`, `Vascular Ehlers-Danlos Syndrome`,
`Aneurysm-Osteoarthritis Syndrome`, and `Rienhoff Syndrome`. Of these, the
`Heritable Thoracic Aortic Disease` grouping currently lists as `members:`
only `Familial Thoracic Aortic Aneurysm and Aortic Dissection`, `Marfan
Syndrome`, `Loeys-Dietz Syndrome`, `Arterial Tortuosity Syndrome`, and
`Shprintzen-Goldberg Syndrome` — it does not yet include `Vascular
Ehlers-Danlos Syndrome`, `Aneurysm-Osteoarthritis Syndrome`, `Rienhoff
Syndrome`, or the separately-curated `Loeys-Dietz Syndrome 4`/`Loeys-Dietz
Syndrome 6` entries (tracked in issue #8866). This entry deliberately keeps
its `genetic:` section to the family-history susceptibility signal (21% of
probands have an affected first-degree relative) rather than re-listing the
HTAD gene panel.
**Partial module conformance.** Three nodes declare `conforms_to` against
`aortopathy_tgfbeta_dysregulation` — the medial degeneration, progressive
dilation, and dissection/rupture nodes, which are the aetiology-independent
final common pathway. The entry deliberately does NOT conform at the module's
upstream `Aortic Wall ECM or Contractile Apparatus Defect` (monogenic lesion)
or `TGF-beta Signaling Dysregulation` nodes: in sporadic degenerative disease
the trigger is acquired hemodynamic/aging injury, and paradoxically increased
TGF-beta signaling is a documented feature of the heritable aortopathies but is
not established as the driver of the sporadic degenerative form. Claiming those
two nodes here would overstate the evidence; the open question is recorded as
the `mismatch_taa_tgfbeta_losartan_translation` discussion rather than asserted
as a mechanism.
**No atherogenesis conformance.** Descending thoracic aneurysm frequently
coexists with aortic atherosclerosis, but thoracic aortic aneurysm and
dissection is mechanistically distinct from atherosclerotic occlusive disease,
so this entry does not conform to the `atherogenesis` module.
**Non-inflammatory qualifier.** Inflammation and oxidative stress are curated
as amplifiers of protease-mediated wall injury (a documented *response* to
aortic injury), not as the initiating lesion. Genuinely inflammatory thoracic
aortic disease (giant cell arteritis, Takayasu arteritis, syphilitic aortitis)
is a distinct entity covered by the `Aortitis` entry.
**Deep research provenance.** Curated with the `claude_code` deep-research
provider (`research/Thoracic_Aortic_Aneurysm-deep-research-claude_code.md`);
no Edison/Falcon, Asta, or OpenScientist key was available in this environment.
Provider output was treated as leads, not ground truth: every PMID was fetched
with `just fetch-reference` and every snippet was checked as an exact
whitespace-normalized substring of the cached abstract before commit. One
candidate ontology term surfaced during drafting (`CHEBI:35567` for
"beta-adrenergic antagonist") proved to denote an unrelated chemical and was
replaced with the verified NCIT drug-class term.
A thoracic aortic aneurysm (TAA) is a permanent, localized dilation of the thoracic aorta — conventionally ≥1.5× the expected normal diameter for the patient's age, sex, and body size — involving the aortic root, ascending aorta, arch, or descending thoracic aorta. TAA is fundamentally a disease of the aortic media: progressive loss of vascular smooth muscle cells (SMCs), fragmentation of elastic lamellae, and accumulation of proteoglycan-rich ground substance ("medial degeneration") weaken the wall so that it dilates under cyclic hemodynamic load, and ultimately dissects or ruptures.
TAA differs mechanistically from abdominal aortic aneurysm (AAA). AAA is dominated by atherosclerosis, transmural inflammation, and adventitial/medial proteolysis in a vessel of neural-crest-independent origin; TAA is predominantly a non-atherosclerotic, non-inflammatory degenerative medial disease in a segment derived largely from cardiac neural crest and second heart field. This distinction is now supported at the level of human genetics: the Million Veteran Program GWAS explicitly concluded (PMID:37308786):
"We leverage multiple downstream analytic methods to identify causal TAAD risk genes and cell types and provide human genetic evidence that TAAD is a non-atherosclerotic aortic disorder distinct from other forms of vascular disease."
TAA is characteristically asymptomatic until catastrophic. Most aneurysms are found incidentally on imaging performed for another indication; the first clinical manifestation in a substantial minority is acute aortic dissection, rupture, or sudden death.
"Thoracic aortic aneurysm" is best modeled as an umbrella/complex entity that subsumes several mechanistically distinct routes to a shared final common pathway:
| Route | Examples | Share of TAA |
|---|---|---|
| Syndromic heritable thoracic aortic disease (HTAD) | Marfan syndrome (FBN1), Loeys-Dietz syndrome (TGFBR1/2, SMAD3, TGFB2/3), vascular Ehlers-Danlos (COL3A1), Shprintzen-Goldberg (SKI), arterial tortuosity syndrome (SLC2A10) | ~5% |
| Nonsyndromic familial TAAD (FTAAD) | ACTA2, MYH11, MYLK, PRKG1, LOX, THSD4, LTBP3, MFAP5, FOXE3 | ~15–20% |
| Bicuspid aortic valve (BAV)-associated aortopathy | NOTCH1 and largely non-Mendelian | ~10–20% of ascending TAA |
| Sporadic / degenerative ("age-related medial degeneration") | Polygenic + hypertension + aging | Majority |
| Secondary / acquired | Post-dissection chronic aneurysm, aortitis (giant-cell, Takayasu, IgG4, syphilitic), infective ("mycotic"), traumatic pseudoaneurysm, post-coarctation, post-surgical | Minority |
The proportion attributable to Mendelian disease is substantial. Renard et al. (PMID:30071989) state:
"Thoracic aortic aneurysms progressively enlarge and predispose to acute aortic dissections. Up to 25% of individuals with thoracic aortic disease harbor an underlying Mendelian pathogenic variant."
| Resource | Identifier | Label |
|---|---|---|
| MONDO | MONDO:0005396 |
thoracic aortic aneurysm ✅ (OAK-verified) |
| MONDO (familial) | MONDO:0019625 |
familial thoracic aortic aneurysm and aortic dissection ✅ |
| MONDO (X-linked) | MONDO:0850095 |
X-linked severe syndromic thoracic aortic aneurysm and dissection ✅ |
| MONDO (veterinary) | MONDO:1012381 |
familial thoracic aortic aneurysm, dog ✅ |
| HPO (phenotype form) | HP:0012727 |
Thoracic aortic aneurysm ✅ |
| ICD-10-CM | I71.1 (thoracic aortic aneurysm, ruptured); I71.2 (thoracic aortic aneurysm, without rupture); I71.5/I71.6 (thoracoabdominal) | |
| ICD-11 | BD50.2 (aneurysm of thoracic aorta) | |
| MeSH | D017544 "Aortic Aneurysm, Thoracic" | |
| Orphanet | ORPHA:91387 (familial thoracic aortic aneurysm and aortic dissection); ORPHA:558 (Marfan syndrome); ORPHA:60030 (Loeys-Dietz); ORPHA:286 (vascular EDS) | |
| OMIM (FTAAD series) | AAT1 607086; AAT3 (TGFBR2) 608967; AAT4 (MYH11) 132900; AAT6 (ACTA2) 611788; AAT7 (MYLK) 613780; AAT8 (PRKG1) 615436; AAT9 (MFAP5) 616166; AAT10 (LOX) 617168; AAT11 (FOXE3) 617349; AAT12 (MAT2A) 618715 | |
| SNOMED CT | 433068007 (Aneurysm of thoracic aorta) |
Thoracic aortic aneurysm; TAA; ascending thoracic aortic aneurysm (ATAA); aortic root aneurysm; annuloaortic ectasia (root-predominant, historic term); descending thoracic aortic aneurysm (DTAA); thoracoabdominal aortic aneurysm (TAAA, when it crosses the diaphragm); thoracic aortic aneurysm and dissection (TAAD) when the aneurysm-and-dissection spectrum is treated as one entity; heritable thoracic aortic disease (HTAD) for the Mendelian subset; familial thoracic aortic aneurysm and dissection (FTAAD); "aortopathy" (in BAV/connective-tissue contexts); historic pathological synonyms cystic medial necrosis / Erdheim medial degeneration — the latter formally deprecated in favor of "medial degeneration" by the Society for Cardiovascular Pathology / AECVP consensus (PMID:27031798).
Information for this entry is mixed-source: - Aggregated disease-level resources: OMIM, Orphanet, ClinGen (gene-disease validity), MONDO, HPO, society guidelines (2022 ACC/AHA PMID:36334952; 2024 EACTS/STS PMID:38416090 / PMID:38408364). - Individual-patient / registry data: International Registry of Acute Aortic Dissection (IRAD; PMID:10685714, PMID:17709637), Olmsted County population cohort (PMID:9851478), Swedish national registers (PMID:17145990), Yale aortic database (PMID:11834007, PMID:16996941), UK Biobank imaging (PMID:34837083), Million Veteran Program EHR + genotype (PMID:37308786), Swedish/Danish administrative pharmacoepidemiology (PMID:29519881). - Molecular / tissue-level: surgical aortic specimens with bulk and single-cell transcriptomics (PMID:33017217), mouse genetics.
The final common pathway is medial degeneration → wall weakening → dilation → dissection/rupture, reached from three broad classes of upstream lesion:
FBN1 (fibrillin-1), COL3A1 (type III procollagen), LOX (lysyl oxidase cross-linking), EFEMP2/FBLN4, MFAP5, THSD4/ADAMTSL6, LTBP3, BGN, ELN.TGFBR1, TGFBR2, SMAD2, SMAD3, TGFB2, TGFB3, SKI. Paradoxically, most are loss-of-function variants yet produce a tissue signature of increased TGF-β signaling.ACTA2 (SMC α-actin), MYH11 (SM myosin heavy chain), MYLK (myosin light chain kinase), PRKG1 (cGMP-dependent protein kinase I). Guo et al. (PMID:23910461) frame this axis explicitly:"Gene mutations that lead to decreased contraction of vascular smooth-muscle cells (SMCs) can cause inherited thoracic aortic aneurysms and dissections."
Superimposed on all three is hemodynamic load (hypertension, abnormal BAV flow jets), aging (elastin has essentially no turnover after adolescence; medial degeneration accumulates), and inflammation in the aortitis subset.
A. Mendelian causal genes. The ClinGen HTAAD Gene Curation Expert Panel evaluated 53 candidate genes and produced the field's reference gene list (PMID:30071989 — paraphrase: 53 genes assessed with the ClinGen framework; 11 genes assigned to the definitive + strong categories and designated "HTAAD genes," with the remainder moderate, limited, or disputed/no-evidence). The definitive/strong set:
| Gene | HGNC (dismech lowercase form) | Protein | Mechanism class | Typical syndrome |
|---|---|---|---|---|
| FBN1 | hgnc:3603 |
fibrillin-1 | ECM microfibril | Marfan syndrome |
| TGFBR1 | hgnc:11772 |
TGF-β receptor I | TGF-β | Loeys-Dietz 1 |
| TGFBR2 | hgnc:11773 |
TGF-β receptor II | TGF-β | Loeys-Dietz 2 |
| SMAD3 | hgnc:6769 |
SMAD3 | TGF-β | Loeys-Dietz 3 / aneurysms-osteoarthritis |
| TGFB2 | hgnc:11768 |
TGF-β2 ligand | TGF-β | Loeys-Dietz 4 |
| TGFB3 | hgnc:11769 |
TGF-β3 ligand | TGF-β | Loeys-Dietz 5 |
| COL3A1 | hgnc:2201 |
type III procollagen | ECM | Vascular EDS |
| ACTA2 | hgnc:130 |
SMC α-actin | Contractile | Nonsyndromic FTAAD (most common) |
| MYH11 | hgnc:7569 |
SM myosin heavy chain | Contractile | FTAAD + PDA |
| MYLK | hgnc:7590 |
myosin light chain kinase | Contractile | FTAAD, dissection at small diameter |
| PRKG1 | hgnc:9414 |
PKG-1 | Contractile | FTAAD, early dissection |
| LOX | hgnc:6664 |
lysyl oxidase | ECM cross-linking | FTAAD |
| SLC2A10 | hgnc:13444 |
GLUT10 | ECM/TGF-β | Arterial tortuosity syndrome (AR) |
| SKI | hgnc:10896 |
SKI proto-oncogene | TGF-β co-repressor | Shprintzen-Goldberg |
| EFEMP2 | hgnc:3219 |
fibulin-4 | ECM elastogenesis | Cutis laxa with aortopathy (AR) |
Newer / emerging genes: THSD4 (hgnc:25835), LTBP3 (hgnc:6716), MFAP5 (hgnc:29673), FOXE3 (hgnc:3808), MAT2A (hgnc:6904), BGN (hgnc:1044, X-linked Meester-Loeys), FLNA (hgnc:3754), NOTCH1 (hgnc:7881, BAV-associated).
Gene-specific effect sizes matter clinically: ACTA2 accounts for the largest share of nonsyndromic FTAAD. Guo et al. (PMID:17994018):
"Here we show that missense mutations in ACTA2 are responsible for 14% of inherited ascending thoracic aortic aneurysms and dissections (TAAD)."
B. Common-variant / polygenic risk. The genetic architecture of sporadic TAA is polygenic. The Million Veteran Program GWAS (PMID:37308786):
"Here, we conducted a genome-wide association study (GWAS) of TAAD, testing ~25 million DNA sequence variants in 8,626 participants with and 453,043 participants without TAAD in the Million Veteran Program, with replication in an independent sample of 4,459 individuals with and 512,463 without TAAD from six cohorts. We identified 21 TAAD risk loci, 17 of which have not been previously reported."
"Our results demonstrate that the genetic architecture of TAAD mirrors that of other complex traits and that it is not solely inherited through protein-altering variants of large effect size."
Deep-learning phenotyping of UK Biobank cardiac MRI further quantified the heritable component of aortic caliber itself (PMID:34837083 — paraphrase: deep learning applied to ~4.6 million cardiac images identified 82 loci for ascending and 47 loci for descending thoracic aortic diameter; a polygenic score for ascending aortic diameter was associated with thoracic aortic aneurysm in 385,621 UK Biobank participants).
C. Chromosomal/structural risk. Turner syndrome (45,X) carries a markedly elevated risk of aortic dilation, BAV, coarctation, and dissection at diameters that would be considered normal in average-sized adults — hence the use of the aortic size index (ASI, cm/m²) rather than absolute diameter in this group. 22q11.2 deletion and Williams-Beuren (ELN) produce arteriopathy that is usually stenotic rather than aneurysmal.
D. Modifier genes. Formal modifier loci are poorly established. Candidate modifiers of the Marfan aortic phenotype include the polygenic background for aortic diameter (PMID:34837083), sex, and variants affecting TGF-β pathway dosage — the Tgfb2^+/- × Fbn1^C1039G/+ double-mutant worsening reported by Lindsay et al. (PMID:22772368) is a proof-of-principle for TGF-β-pathway gene dosage as a modifier:
"Mice that harbor both a mutant Marfan syndrome (MFS) allele (Fbn1(C1039G/+)) and Tgfb2 haploinsufficiency show increased TGF-β signaling and phenotypic worsening in association with normalization of TGF-β2 expression and high expression of TGF-β1."
| Factor | Effect | Notes |
|---|---|---|
| Hypertension | Strongest modifiable risk factor for dissection | IRAD: history of hypertension predicted dissection at diameter <5.5 cm (OR 2.17, 95% CI 1.03–4.57; PMID:17709637) |
| Increasing age | Strong | Degenerative medial change accumulates; Clouse mean age at recognition 75.9 y (women) vs 62.8 y (men) (PMID:9851478) |
| Male sex | Higher incidence; female sex confers worse outcome per unit diameter | Olsson: 16.3 vs 9.1 per 100,000/yr (PMID:17145990) |
| Smoking / COPD | Increases risk, especially descending TAA | Shared with AAA |
| Atherosclerosis, dyslipidemia | Predominantly descending/arch TAA | Less relevant to root/ascending |
| Bicuspid aortic valve | ~0.5–2% population prevalence; 8–10× dissection risk vs tricuspid | NOTCH1 (PMID:16025100) plus non-Mendelian |
| Cocaine, amphetamines, weightlifting/Valsalva | Acute dissection triggers | dP/dt and BP surges |
| Pregnancy (3rd trimester/peripartum) | Dissection trigger in HTAD | Hemodynamic + hormonal medial change |
| Fluoroquinolone antibiotics | Associated with aneurysm/dissection | See below |
| Anabolic steroids | Case-associated | Weak evidence |
| Inflammatory aortitis | Giant cell arteritis, Takayasu, IgG4-RD, rheumatoid, ankylosing spondylitis | Distinct etiologic arm |
| Infection | Treponema pallidum (syphilitic aortitis), Salmonella, Staphylococcus (mycotic aneurysm) | Rare in high-income settings |
| Prior aortic surgery / coarctation repair / deceleration trauma | Pseudoaneurysm, chronic post-dissection aneurysm |
Fluoroquinolones. Pasternak et al., nationwide Swedish cohort (PMID:29519881):
"Within the 60 day risk period, the rate of aortic aneurysm or dissection was 1.2 cases per 1000 person years among fluoroquinolone users and 0.7 cases per 1000 person years among amoxicillin users. Fluoroquinolone use was associated with an increased risk of aortic aneurysm or dissection (hazard ratio 1.66 (95% confidence interval 1.12 to 2.46)), with an estimated absolute difference of 82 (95% confidence interval 15 to 181) cases of aortic aneurysm or dissection by 60 days per 1 million treatment episodes."
Mechanistic support comes from a mouse challenge study — LeMaire et al., JAMA Surgery 2018 (PMID:30046809, "Effect of Ciprofloxacin on Susceptibility to Aortic Dissection and Rupture in Mice"), which is MODEL_ORGANISM evidence and should be tagged as such. FDA and EMA both issued warnings against fluoroquinolone use in patients with, or at risk for, aortic aneurysm. Ciprofloxacin: CHEBI:100241 ✅.
Evidence here is thin and largely inferential: - Blood-pressure control (β-blockade, ARB, strict BP targets) reduces aortic growth rate — see §12. - Statins — observational association with reduced aneurysm growth; no randomized proof in TAA. - Avoidance of isometric/maximal-exertion straining — guideline-endorsed behavioral protection, not RCT-tested. - Genetic protective factors — none established. Protective common variants at the 21 MVP loci exist by construction (each locus has a protective allele; e.g. loci near FBN1, TCF7L2, ULK4, LRP1, ELN), but no discrete "protective allele" of clinical utility has been validated. - Diabetes mellitus is inversely associated with abdominal aortic aneurysm; the protective association is weaker and less consistent for thoracic disease and should not be curated as established for TAA.
The clinically dominant G×E interaction is genotype × hemodynamic stress: - In HTAD, hypertension and exertional BP surges accelerate a genetically weakened media; this is precisely why β-blockers/ARBs plus activity restriction are prescribed on the basis of genotype, not diameter alone. - Genotype × pregnancy: vascular EDS and Loeys-Dietz carry disproportionate peripartum dissection/uterine-rupture risk. Pepin et al. (PMID:10706896): "Complications of pregnancy led to death in 12 of the 81 women who became pregnant." - Genotype × fluoroquinolone: because ciprofloxacin inhibits ECM homeostasis and increases MMP activity, guideline bodies advise avoidance specifically in HTAD/Marfan patients — an explicitly genotype-conditioned exposure recommendation. - BAV × flow: the eccentric systolic jet of a bicuspid valve imposes an asymmetric wall-shear-stress field on the convexity of the ascending aorta, where the aneurysm preferentially forms — a structural genotype interacting with a purely physical exposure.
TAA is silent in the large majority of patients until a complication occurs. Phenotype curation should therefore be split into (a) the structural/imaging phenotype, (b) compressive/local symptoms of a large aneurysm, (c) acute complication phenotypes, and (d) syndrome-associated systemic phenotypes when a Mendelian cause is present.
| Phenotype | HPO term | Verified | Onset | Severity | Course | Frequency |
|---|---|---|---|---|---|---|
| Thoracic aortic aneurysm | HP:0012727 Thoracic aortic aneurysm |
✅ | Adult (sporadic); childhood–young adult (HTAD) | Variable | Progressive | Obligate (definitional) |
| Aortic root aneurysm | HP:0002616 Aortic root aneurysm |
✅ | Childhood in Marfan/LDS | Variable | Progressive | Very frequent in syndromic HTAD |
| Ascending aortic aneurysm | HP:0004970 Ascending tubular aorta aneurysm |
✅ | Adult | Variable | Progressive | ~60% of TAA |
| Descending TAA (fusiform) | HP:0012728 Fusiform descending thoracic aortic aneurysm |
✅ | Older adult | Variable | Progressive | ~30% |
| Descending TAA (saccular) | HP:0012729 Saccular descending thoracic aortic aneurysm |
✅ | Older adult | Higher rupture risk per size | Progressive | Minority |
| Aortic aneurysm (parent) | HP:0004942 Aortic aneurysm |
✅ | — | — | — | — |
| Arterial tortuosity | HP:0005116 Arterial tortuosity |
✅ | Childhood | Marker of severity | Stable/progressive | LDS, ATS; Marfan (severity marker, PMID:26005802) |
| Bicuspid aortic valve | HP:0001647 Bicuspid aortic valve |
✅ | Congenital | — | Stable | ~10–20% of ascending TAA |
| Mitral valve prolapse | HP:0001634 Mitral valve prolapse |
✅ | Childhood/adult | Mild–moderate | Progressive | Frequent in Marfan |
| Aortic regurgitation | HP:0001659 Aortic regurgitation |
✅ | Follows root dilation | Mild–severe | Progressive | Frequent with root aneurysm ≥5 cm |
| Patent ductus arteriosus | HP:0001643 Patent ductus arteriosus |
✅ | Congenital | — | — | Characteristic of MYH11-TAAD (PMID:16444274) |
| Abdominal aortic aneurysm (concurrent) | HP:0005112 Abdominal aortic aneurysm |
✅ | Adult | — | Progressive | 24.9% of TAA probands/kindreds had AAA (PMID:16996941) |
| Phenotype | HPO term | Verified | Notes |
|---|---|---|---|
| Chest pain | HP:0100749 Chest pain |
✅ | Deep, aching, or (in dissection) abrupt tearing/ripping |
| Hoarse voice | HP:0001609 Hoarse voice |
✅ | Left recurrent laryngeal nerve stretch (Ortner/cardiovocal syndrome) — arch aneurysm |
| Dysphagia | HP:0002015 Dysphagia |
✅ | Esophageal compression (dysphagia aortica) |
| Hemoptysis | HP:0002105 Hemoptysis |
✅ | Aorto-bronchial fistula / erosion — herald bleed |
| Syncope | HP:0001279 Syncope |
✅ | Tamponade, rupture, or arch-vessel malperfusion |
| Sudden death | HP:0001699 Sudden death |
✅ | Rupture/tamponade; often the presenting event |
| Aortic dissection | HP:0002647 Aortic dissection |
✅ | The dominant lethal complication |
| Aortic rupture | HP:0031649 Aortic rupture |
✅ | |
| Hypertension | HP:0000822 Hypertension |
✅ | Both cause and consequence |
| Ischemic stroke | HP:0002140 Ischemic stroke |
✅ | Dissection-related malperfusion |
| Transient ischemic attack | HP:0002326 Transient ischemic attack |
✅ |
Other classically described but ontology-unverified features to look up before curating: dyspnea (HP:0002094), superior vena cava syndrome, Horner syndrome from sympathetic chain compression, cough/stridor from tracheobronchial compression, back/interscapular pain (descending TAA), pulse deficit and new diastolic murmur in dissection, and Cardarelli/Oliver sign (tracheal tug).
Note on the IRAD presentation data (PMID:10685714): "While sudden onset of severe sharp pain was the single most common presenting complaint, the clinical presentation was diverse. Classic physical findings such as aortic regurgitation and pulse deficit were noted in only 31.6% and 15.1% of patients, respectively."
TAA has no diagnostic laboratory test. Investigational and complication-related markers: - D-dimer — highly sensitive but non-specific for acute aortic dissection; used as a rule-out adjunct with the aortic dissection detection risk score. LOINC 48065-7 / 48066-5. - Soluble ST2, matrix metalloproteinase-9 (MMP-9), TGF-β1, tenascin-C, smooth muscle myosin heavy chain — investigational circulating biomarkers; none guideline-endorsed. - Complication markers: rising lactate and creatinine (malperfusion), troponin (coronary ostial involvement), falling hemoglobin (rupture), leukocytosis and CRP (aortitis, or the acute-phase response to dissection). - Aortitis workup: ESR, CRP, IgG4 subclass, RPR/treponemal serology, blood cultures.
FBN1 (hgnc:3603; OMIM 134797) — Marfan syndrome.
Fibrillin-1 is the structural backbone of extracellular microfibrils and the reservoir that sequesters latent TGF-β–binding-protein (LTBP)-bound TGF-β. Both haploinsufficiency and dominant-negative mechanisms operate; cysteine-substituting missense variants in cbEGF domains (e.g. C1039G) and premature-termination alleles are the two archetypes. Judge et al. (PMID:15254584) established that haploinsufficiency alone is sufficient. The functional link from matrix to signaling is Neptune et al. (PMID:12598898):
"We show that mice deficient in fibrillin-1 have marked dysregulation of transforming growth factor-beta (TGF-beta) activation and signaling, resulting in apoptosis in the developing lung."
"These data indicate that matrix sequestration of cytokines is crucial to their regulated activation and signaling and that perturbation of this function can contribute to the pathogenesis of disease."
ACTA2 (hgnc:130) — the most common nonsyndromic FTAAD gene.
Missense variants act as dominant negatives on actin filament assembly (PMID:17994018):
"Structural analyses and immunofluorescence of actin filaments in SMCs derived from individuals heterozygous for ACTA2 mutations illustrate that these mutations interfere with actin filament assembly and are predicted to decrease SMC contraction. Aortic tissues from affected individuals showed aortic medial degeneration, focal areas of medial SMC hyperplasia and disarray, and stenotic arteries in the vasa vasorum due to medial SMC proliferation."
The specific recurrent de novo ACTA2 p.Arg179His allele produces a distinct, severe multisystem disease — multisystemic smooth muscle dysfunction syndrome (PMID:20734336; paraphrase: de novo R179H causes aortic and cerebrovascular disease with fixed dilated pupils, hypotonic bladder, malrotation, gut hypoperistalsis and pulmonary hypertension). This is an important genotype–phenotype distinction to model as a subtype.
MYH11 (hgnc:7569) — TAAD with PDA, dominant-negative. (PMID:16444274):
"We now demonstrate that the disease is caused by mutations in the MYH11 gene affecting the C-terminal coiled-coil region of the smooth muscle myosin heavy chain, a specific contractile protein of smooth muscle cells (SMC). All individuals bearing the heterozygous mutations, even if asymptomatic, showed marked aortic stiffness. Examination of pathological aortas showed large areas of medial degeneration with very low SMC content."
"Abnormal immunological recognition of SM-MHC and the colocalization of wild-type and mutant rod proteins in SMC, in conjunction with differences in their coimmunoprecipitation capacities, strongly suggest a dominant-negative effect."
MYLK (hgnc:7590) — loss of function; dissection at near-normal diameter. Clinically the most important "aneurysm-negative dissection" gene (PMID:21055718):
"Both families demonstrated a similar phenotype characterized by presentation with an acute aortic dissection with little to no enlargement of the aorta."
"The p.R1480X mutation leads to a truncated protein lacking the kinase and calmodulin binding domains, and p.S1759P alters amino acids in the α-helix of the calmodulin binding sequence, which disrupts kinase binding to calmodulin and reduces kinase activity in vitro."
PRKG1 (hgnc:9414) — recurrent gain-of-function p.Arg177Gln. (PMID:23910461):
"Exome sequencing of distant relatives affected by thoracic aortic disease and subsequent Sanger sequencing of additional probands with familial thoracic aortic disease identified the same rare variant, PRKG1 c.530G>A (p.Arg177Gln), in four families. This mutation segregated with aortic disease in these families with a combined two-point LOD score of 7.88. The majority of affected individuals presented with acute aortic dissections (63%) at relatively young ages (mean 31 years, range 17-51 years)."
"Although the p.Arg177Gln alteration disrupts binding to the high-affinity cGMP binding site within the regulatory domain, the altered PKG-1 is constitutively active even in the absence of cGMP. The increased PKG-1 activity leads to decreased phosphorylation of the myosin regulatory light chain in fibroblasts and is predicted to cause decreased contraction of vascular SMCs."
LOX (hgnc:6664) — impaired elastin/collagen cross-linking. Lee et al. (PMID:27432961 — paraphrase: whole-genome sequencing in cousins with thoracic aortic disease identified a segregating LOX missense allele; a knock-in mouse recapitulated the disease). A short verbatim fragment retrieved: "Mice homozygous for the human allele died shortly after parturition from ascending aortic aneurysm and spontaneous hemorrhage." — re-verify before use.
THSD4 (hgnc:25835) / ADAMTSL6 — haploinsufficiency impairing fibrillin-1 assembly. (PMID:32855533):
"We identified five functional variants in THSD4 of which two heterozygous variants lead to a premature termination codon. THSD4 encodes ADAMTSL6 (member of the ADAMTS/L superfamily), a microfibril-associated protein that promotes fibrillin-1 matrix assembly. The THSD4 variants studied lead to haploinsufficiency or impaired assembly of fibrillin-1 microfibrils. Thsd4+/- mice showed progressive dilation of the thoracic aorta."
TGF-β axis genes. SMAD3 (PMID:21217753):
"We delineated a new syndrome presenting with aneurysms, dissections and tortuosity throughout the arterial tree in association with mild craniofacial features and skeletal and cutaneous anomalies. In contrast with other aneurysm syndromes, most of these affected individuals presented with early-onset osteoarthritis. We mapped the genetic locus to chromosome 15q22.2-24.2 and show that the disease is caused by mutations in SMAD3. ... SMAD3 mutations lead to increased aortic expression of several key players in the TGF-β pathway, including SMAD3."
TGFBR1/TGFBR2 (PMID:15731757, Loeys-Dietz syndrome). TGFB2 (PMID:22772368) crystallizes the central paradox:
"Loeys-Dietz syndrome (LDS) associates with a tissue signature for high transforming growth factor (TGF)-β signaling but is often caused by heterozygous mutations in genes encoding positive effectors of TGF-β signaling, including either subunit of the TGF-β receptor or SMAD3, thereby engendering controversy regarding the mechanism of disease."
"Taken together, these data support the hypothesis that compensatory autocrine and/or paracrine events contribute to the pathogenesis of TGF-β-mediated vasculopathies."
COL3A1 (hgnc:2201) — vascular EDS. Mostly glycine-substitution missense and splice variants in the triple-helical domain (dominant negative); haploinsufficiency (null) alleles are milder. Pepin et al. (PMID:10706896):
"Complications were rare in childhood; 25 percent of the index patients had a first complication by the age of 20 years, and more than 80 percent had had at least one complication by the age of 40. The calculated median survival of the entire cohort was 48 years. Most deaths resulted from arterial rupture."
"The types of complications were not associated with specific mutations in COL3A1."
NOTCH1 (hgnc:7881) — BAV and aortic valve disease. Garg et al., Nature 2005 (PMID:16025100).
LTBP3 (hgnc:6716) — Guo et al., AJHG 2018 (PMID:29625025, "LTBP3 Pathogenic Variants Predispose Individuals to Thoracic Aortic Aneurysms and Dissections").
PM1 hotspots exist (e.g. FBN1 cbEGF cysteines; ACTA2 R179, R258, R118; PRKG1 R177). ClinVar is the reference submission repository; ~30–40% of rare FBN1 missense submissions remain VUS.PM2 criterion. Conversely, the 21 MVP GWAS loci are common variants of small effect (OR typically 1.05–1.25).This is the chain the dismech module aortopathy_tgfbeta_dysregulation already encodes, and a TAA entry should declare conforms_to against its nodes:
[trigger] Aortic wall ECM defect OR SMC contractile-apparatus defect OR hemodynamic overload
↓
Impaired SMC–matrix mechanosensing / loss of contractile tone
↓
TGF-β signaling dysregulation (paradoxical increase in canonical pSmad2/3 and
noncanonical ERK1/2–JNK output; AT1R-dependent component)
↓
Medial degeneration: SMC apoptosis + phenotypic modulation, elastic fiber
fragmentation, proteoglycan/glycosaminoglycan pooling, MMP-2/MMP-9 activation
↓
Loss of tensile strength and increased wall stress (Laplace: σ ∝ P·r/2t)
↓
Progressive aortic dilation (positive-feedback: larger radius → higher wall stress)
↓
Intimal tear → aortic dissection | Wall failure → aortic rupture
↓
Tamponade, malperfusion, exsanguination, death
Suggested conformance targets: aortopathy_tgfbeta_dysregulation#TGF-beta Signaling Dysregulation (canonical hub), plus the medial-degeneration and dilation nodes. Note also the deliberate exclusion of atherogenesis — the MVP GWAS explicitly establishes TAAD as non-atherosclerotic (PMID:37308786), so a TAA entry should not conform to atherogenesis, unlike an AAA or coronary entry. Post-dissection thrombosis of the false lumen may justify a link to thrombogenesis.
| Pathway | Role | Key nodes |
|---|---|---|
| TGF-β / SMAD | Central, and paradoxical | Latent TGF-β sequestered by LTBP–fibrillin-1; matrix failure releases it; canonical TGFBR1/2 → pSMAD2/3 → SMAD4 → nuclear target genes. GO:0007179 ✅ "transforming growth factor beta receptor signaling pathway" |
| Noncanonical TGF-β (ERK1/2, JNK, p38) | Aneurysm-driving arm; ERK inhibition rescues LDS mice | MAP kinase cascade |
| Angiotensin II / AT1R | Upstream amplifier of TGF-β; therapeutic target | AGTR1 → TGF-β ligand and receptor upregulation |
| SMC contraction / actomyosin | Force generation and mechanotransduction | ACTA2–MYH11 cross-bridge cycling; MYLK phosphorylates RLC; PRKG1/PKG-1 and MYPT1 dephosphorylate it. GO:0006939 ✅ "smooth muscle contraction" |
| NO–cGMP–PKG | Relaxation arm; PRKG1 GoF locks it on | sGC → cGMP → PKG-1 |
| ECM assembly and cross-linking | Structural | GO:0030198 ✅ "extracellular matrix organization"; GO:0030199 ✅ "collagen fibril organization"; GO:0048251 ✅ "elastic fiber assembly"; GO:0004720 ✅ "protein-lysine 6-oxidase activity" (LOX) |
| MMP / TIMP proteolysis | Executes matrix destruction | MMP-2, MMP-9, MMP-12; TIMP-1/2/3 |
| Integrin / focal adhesion mechanotransduction | Links matrix stiffness to SMC phenotype | αvβ3, α5β1, FAK, RhoA/ROCK, YAP/TAZ |
| Inflammation | Secondary in degenerative TAA; primary in aortitis | GO:0006954 ✅ "inflammatory response"; IL-6, IL-1β, NF-κB |
| Oxidative stress / mitochondrial dysfunction | Amplifier | GO:0006979 ✅ "response to oxidative stress"; NOX enzymes, uncoupled eNOS |
| Aortic developmental patterning | Explains segmental susceptibility | GO:0035904 ✅ "aorta development"; cardiac neural crest vs second heart field lineage boundary at the sinotubular junction |
| SMC migration/phenotype switching | Modulated/synthetic SMC | GO:0014909 ✅ "smooth muscle cell migration" |
The founding observation is that Fbn1-deficient tissue shows excess TGF-β activity, and TGF-β antagonism rescues the phenotype. Habashi et al. (PMID:16601194):
"We show that aortic aneurysm in a mouse model of MFS is associated with increased TGF-beta signaling and can be prevented by TGF-beta antagonists such as TGF-beta-neutralizing antibody or the angiotensin II type 1 receptor (AT1) blocker, losartan. AT1 antagonism also partially reversed noncardiovascular manifestations of MFS, including impaired alveolar septation."
But the direction of the TGF-β effect is time- and context-dependent. Cook et al. (PMID:25614286, paraphrase with verbatim fragments):
"Aneurysm growth, media degeneration, aortic levels of phosphorylated Erk and Smad proteins and the average survival of Fbn1(mgR/mgR) mice were compared after a ≈3-month-long treatment with placebo and either the AT1r antagonist losartan or the TGFβ-neutralizing antibody 1D11."
"TGFβ neutralization either exacerbated or mitigated TAA formation depending on whether treatment was initiated before or after aneurysm formation."
Combined with the loss-of-function nature of TGFBR1/2, SMAD3, and TGFB2/3 variants (PMID:22772368), the field's current reading is that early TGF-β signaling is protective/homeostatic for the aortic media, and the late excess seen in diseased tissue is a compensatory, and then maladaptive, response. Curation guidance: model the "increased TGF-β signaling drives aneurysm" edge inside a mechanistic_hypotheses group (status ALTERNATIVE or EMERGING) rather than asserting it as canonical, and attach a KNOWLEDGE_GAP or HUMAN_MODEL_MISMATCH discussion — the losartan mouse result (PMID:16601194) did not translate into superiority over β-blockade in humans (PMID:25405392), which is a textbook model-to-human mismatch.
| Cell type | CL term | Verified | Role |
|---|---|---|---|
| Vascular smooth muscle cell | CL:0000359 vascular associated smooth muscle cell |
✅ | Central effector; apoptosis, phenotypic modulation, loss of contractility |
| Smooth muscle cell (generic) | CL:0000192 smooth muscle cell |
✅ | |
| Vascular endothelial cell | CL:0002139 endothelial cell of vascular tree |
✅ | Mechanosensing of wall shear stress; endothelial dysfunction; intimal tear origin |
| Fibroblast (adventitial) | CL:0000057 fibroblast |
✅ | Adventitial remodeling, myofibroblast transition, collagen deposition |
| Macrophage | CL:0000235 macrophage |
✅ | MMP source; expanded in aneurysm tissue |
| T cell | CL:0000084 T cell |
✅ | Expanded in ATAA per scRNA-seq (PMID:33017217) |
Key cellular processes: SMC apoptosis and anoikis; SMC phenotypic modulation from contractile (ACTA2, MYH11, CNN1, TAGLN high) to synthetic/modulated/fibromyocyte states; impaired autophagy; senescence; mitochondrial dysfunction; adventitial neovascularization and vasa vasorum stenosis (documented in ACTA2 aortas — PMID:17994018).
In degenerative and heritable TAA, inflammation is a secondary amplifier, not the initiating event — historically the field's reason for calling it "non-inflammatory degenerative" disease. However, single-cell data show a real immune shift (PMID:33017217):
"In general, ATAA tissues had fewer nonimmune cells and more immune cells, especially T lymphocytes, than control tissues did."
In aortitis (giant-cell arteritis, Takayasu, IgG4-related disease, syphilis, ANCA-associated, relapsing polychondritis, Behçet), immunity is primary: granulomatous or lymphoplasmacytic transmural infiltration destroys the media and produces aneurysm. This subset responds to immunosuppression (glucocorticoids, tocilizumab, rituximab) and should be a separately modeled etiologic arm.
Transcriptomics. Consistent findings across bulk and single-cell studies: downregulation of the contractile SMC gene program (ACTA2, MYH11, CNN1, TAGLN, MYOCD); upregulation of synthetic/ECM-remodeling genes; interferon and inflammatory signatures in dissection specimens. The landmark human scRNA-seq resource is PMID:33017217:
"We identified 11 major cell types in human ascending aortic tissue; the high-resolution reclustering of these cells further divided them into 40 subtypes. Multiple subtypes were observed for smooth muscle cells, macrophages, and T lymphocytes, suggesting that these cells have multiple functional populations in the aortic wall."
with an integrative GWAS/Hi-C finding:
"integrative analysis of our single-cell RNA sequencing data with public genome-wide association study data and promoter capture Hi-C data suggested that the erythroblast transformation-specific related gene(ERG) exerts an important role in maintaining normal aortic wall function."
Additional single-cell resources: "Dissecting the Heterogeneity of Human Thoracic Aortic Aneurysms Using Single-Cell Transcriptomics" (ATVB 2022) and the Il1rn⁺/Trem1⁺ macrophage subpopulation study (Cell Discovery 2021) — obtain PMIDs before citing.
Proteomics. Aortic-wall proteomics reproducibly shows reduced contractile and cytoskeletal proteins with increased ECM-remodeling and stress-response proteins. Plasma proteomic candidates (MMP-9, TIMP-1, TGF-β1, tenascin-C, sST2, thrombospondin) have not achieved clinical validation. PRIDE/ProteomeXchange hold the deposited datasets.
Metabolomics/lipidomics. Small human studies report altered acylcarnitines, branched-chain amino acids, and sphingolipids in TAA vs control aorta and plasma. Nothing clinically actionable; MetaboLights/Metabolomics Workbench are the repositories.
Spatial transcriptomics and multi-omics. Recent work maps the intramural gradient of SMC phenotype from intima to adventitia and localizes GAG-pooling foci. A 2023 multi-omic study of familial TAAD implicated impaired calcium transport as a dissection-predisposing lesion (PMC10607035 — retrieve PMID before citing).
Functional genomics. No large TAA-specific CRISPR screen exists. Patient-derived iPSC-derived vascular SMCs are the dominant functional platform, and importantly show lineage-specific vulnerability: neural-crest-derived iPSC-SMCs (the lineage of the ascending aorta/root) reproduce the Marfan/LDS contractile and ECM defect while lateral-plate-mesoderm-derived SMCs do not — the leading cell-autonomous explanation for why disease is segment-restricted.
Primary: the thoracic aorta. UBERON:0001515 thoracic aorta ✅. Segment-specific:
| Segment | UBERON | Verified | Notes |
|---|---|---|---|
| Aortic root / sinuses of Valsalva | UBERON:0003707 sinus of Valsalva |
✅ | Marfan, LDS, BAV-root phenotype; "annuloaortic ectasia" |
| Ascending aorta | UBERON:0001496 ascending aorta |
✅ | Most common TAA site (~60%) |
| Aortic arch | UBERON:0001508 arch of aorta |
✅ | ~10%; recurrent laryngeal/tracheal compression |
| Descending thoracic aorta | UBERON:0001515 thoracic aorta |
✅ | ~30%; smoking/atherosclerosis-associated |
| Aorta (parent) | UBERON:0000947 aorta |
✅ | |
| Aortic valve | UBERON:0002137 aortic valve |
✅ | BAV; secondary regurgitation from annular dilation |
Secondary organ involvement (complications): - Heart — aortic regurgitation → LV volume overload and heart failure; hemopericardium/tamponade; coronary ostial dissection → myocardial infarction. - Brain — malperfusion stroke, and in ACTA2/HTAD, independent intracranial arteriopathy (moyamoya-like, intracranial aneurysm). - Kidney, gut, spinal cord, limbs — branch-vessel malperfusion in dissection; paraplegia from artery-of-Adamkiewicz compromise (both from dissection and as a TEVAR/open-repair complication). - Lung/airway/esophagus/laryngeal nerve — compression; aorto-bronchial and aorto-esophageal fistula. - Vertebrae/sternum — erosion by chronic saccular aneurysm.
Body systems: cardiovascular (primary); respiratory, nervous, digestive, renal, musculoskeletal (secondary). In syndromic HTAD, add ocular (ectopia lentis in Marfan), skeletal (dolichostenomelia, pectus, scoliosis), integumentary (striae, translucent skin), and craniofacial (hypertelorism, bifid uvula in LDS).
UBERON:0003618 aorta tunica media ✅ (parent UBERON:0002522 tunica media ✅). Aortic SMC tissue: UBERON:0004178 aorta smooth muscle tissue ✅.The aorta is a midline unpaired structure — laterality is not applicable in the usual sense. Two spatial patterns matter instead:
Aneurysm shape should be curated too: fusiform (circumferential, degenerative/heritable) vs saccular (eccentric outpouching; higher rupture risk per size; typical of mycotic, post-traumatic, and penetrating-ulcer aneurysms).
| Context | Typical age of aneurysm detection | Onset pattern |
|---|---|---|
| Sporadic/degenerative | 60s–70s (Clouse: women 75.9 y, men 62.8 y — PMID:9851478) | Insidious, asymptomatic |
| Familial nonsyndromic TAAD | ~58 y (PMID:16996941) | Insidious |
| Marfan syndrome | Childhood–young adulthood (~27 y at presentation, PMID:16996941) | Insidious, congenital substrate |
| Loeys-Dietz syndrome | Childhood, often <10 y | Aggressive, early |
| ACTA2 R179 (MSMDS) | Infancy | Congenital multisystem |
| Vascular EDS | Complications from adolescence; 25% by age 20, >80% by age 40 (PMID:10706896) | Episodic catastrophes |
| BAV aortopathy | 40s–60s | Insidious |
Albornoz et al. quantified the familial-vs-sporadic-vs-Marfan age gradient (PMID:16996941):
"The familial TAA group was significantly younger than the sporadic group (p < 0.0001), but not as young as the MFS group (p < 0.0001) (mean ages, 58.2 versus 65.7 versus 27.4 years)."
Stages (a practical clinical staging, no formal consensus system exists):
| Stage | Definition | Management |
|---|---|---|
| At-risk / genotype-positive, phenotype-negative | Pathogenic HTAD variant, normal aortic dimensions | Surveillance, BP control, activity counseling |
| Early dilation | Diameter above normal but below threshold (e.g. root Z 2–3, or 4.0–4.4 cm) | Annual imaging, medical therapy |
| Intermediate aneurysm | 4.5–5.4 cm (or genotype-specific equivalent) | 6–12-month imaging; surgical planning |
| Surgical-threshold aneurysm | ≥5.5 cm sporadic; ≥5.0 cm Marfan/experienced center; ≥4.0–4.5 cm in high-risk genotypes; rapid growth; symptoms; concomitant cardiac surgery | Elective repair |
| Acute complication | Dissection (Stanford A/B; DeBakey I/II/III), intramural hematoma, penetrating atherosclerotic ulcer, contained or free rupture | Emergency |
| Chronic post-dissection | Residual false lumen aneurysmal degeneration | Lifelong surveillance; reintervention in 20–40% |
Growth rate. Slow and nonlinear — it accelerates with diameter. Davies et al. (PMID:11834007): "The aorta grew at a mean of 0.10 cm per year." Albornoz et al. (PMID:16996941):
"Aortic growth rate was highest for the familial group (0.21 cm/y), intermediate for the sporadic group (0.16 cm/y), and lowest for the Marfan group (0.1 cm/y; p < 0.01)."
"Familial TAAs tend to grow at a higher rate, exemplifying a more aggressive clinical entity."
(The apparently low Marfan rate reflects treatment and early surgical referral, not benign biology.)
Event rates by size. Davies et al. (PMID:11834007):
"For aneurysms greater than 6 cm in diameter, rupture occurred at 3.7% per year, rupture or dissection at 6.9% per year, death at 11.8%, and death, rupture, or dissection at 15.6% per year. At size greater than 6.0 cm, the odds ratio for rupture was increased 27-fold (p = 0.0023)."
Clouse et al. (PMID:9851478):
"The cumulative risk of rupture was 20% after 5 years. Seventy-nine percent of ruptures occurred in women (P= .01). The 5-year risk of rupture as a function of aneurysm size at recognition was 0% for aneurysms less than 4 cm in diameter, 16% (95% CI, 4%-28%) for those 4 to 5.9 cm, and 31% (95% CI, 5%-56%) for aneurysms 6 cm or more."
The critical caveat — size is a poor predictor of dissection. Pape et al., IRAD (PMID:17709637):
"Maximum aortic diameters averaged 5.3 cm; 349 (59%) patients had aortic diameters <5.5 cm and 229 (40%) patients had aortic diameters <5.0 cm."
"The majority of patients with acute type A acute aortic dissection present with aortic diameters <5.5 cm and thus do not fall within current guidelines for elective aneurysm surgery. Methods other than size measurement of the ascending aorta are needed to identify patients at risk for dissection."
Also from that paper: "Marfan syndrome patients were more likely to dissect at larger diameters (odds ratio, 14.3; 95% confidence interval, 2.7 to 100; P=0.002)" — i.e., Marfan patients dissect at larger absolute diameters than the sporadic population, which is one reason the guideline threshold for Marfan is set on Z-score/relative rather than purely absolute grounds.
Course pattern: chronic and progressive with episodic catastrophic punctuation. There is no spontaneous remission — an aneurysm does not regress. The only "remission" is treatment-induced (surgical replacement of the diseased segment). Disease duration is lifelong; even after repair, the residual native aorta remains at risk, and reoperation is common (Olsson: "The cumulative incidence of thoracic aortic reoperations was 7.8% at 10 years." — PMID:17145990).
Critical intervention windows: (i) presymptomatic detection via family screening or incidental imaging; (ii) the window between reaching the surgical threshold and dissecting — the whole rationale for elective repair; (iii) pre-pregnancy counseling and root repair in HTAD women; (iv) the first 48 hours of acute type A dissection, where mortality is ~1–2% per hour untreated.
| Measure | Value | Source |
|---|---|---|
| Incidence (Olmsted County, USA, 1980–1994) | 10.4 per 100,000 person-years (95% CI 8.6–12.2) | PMID:9851478 — "more than 3-fold higher than the rate from 1951 to 1980" |
| Incidence (Sweden, national, to 2002) | 16.3 per 100,000/yr men; 9.1 per 100,000/yr women | PMID:17145990 — "Incidence of thoracic aortic disease rose by 52% in men and by 28% in women" |
| Acute aortic dissection incidence | ~3–6 per 100,000/yr | IRAD-era estimates |
| Population prevalence of ascending aortic dilation | ~0.5–1% of adults by imaging | UK Biobank / population CT-echo studies |
| BAV prevalence | 0.5–2% of population | Contributes ~10–20% of ascending TAA |
| Fraction with a Mendelian cause | up to 25% | PMID:30071989 |
| Fraction of non-Marfan TAA with a family history | 21.5% | PMID:16996941 — "An inherited pattern for TAA was present in 21.5% of non-MFS patients." |
| Marfan syndrome prevalence | ~1 in 5,000 (2–3 per 10,000; Orphanet class 1–5/10,000) | ORPHA:558 |
| Loeys-Dietz prevalence | <1 in 100,000 (ultra-rare) | ORPHA:60030 |
| Vascular EDS prevalence | ~1 in 50,000–200,000 | ORPHA:286 |
For dismech Prevalence records, model these with explicit measure_type — the Olmsted and Swedish figures are ANNUAL_INCIDENCE, not prevalence, and should carry prevalence_class: BAND_1_9_PER_100000 with rate_per_100000 of 10.4 / 16.3 / 9.1 respectively. Do not compare them to Orphanet point-prevalence classes.
Olsson et al. also documented rising ascertainment and improving outcomes (PMID:17145990):
"The prevalence and incidence of thoracic aortic disease was higher than previously reported and increasing. The annual number of operations increased substantially. Surgical (30-day) and long-term survival improved significantly over time to form a growing cohort of patients needing counseling, management decisions, operations, and extended postoperative surveillance."
HP:0000006 Autosomal dominant inheritance (verify with OAK).HP:0000007 (verify).HP:0001417/HP:0001419 (verify).HP:0010982 Polygenic inheritance would be the appropriate binding for a susceptibility-typed Genetic block.| Modality | Role | NCIT | Verified |
|---|---|---|---|
| CT angiography (contrast, ECG-gated) | Reference standard for diagnosis, sizing, surgical planning, and emergency dissection triage; whole-aorta coverage | NCIT:C202408 Computed Tomography Angiography |
✅ |
| Multi-detector CTA | NCIT:C157338 Multi-detector Computed Tomography Angiography |
✅ | |
| Transthoracic echocardiography | First-line for aortic root/proximal ascending and valve; surveillance in Marfan children | NCIT:C80404 Transthoracic Echocardiography Test |
✅ |
| Transesophageal echocardiography | Intraoperative and unstable-patient dissection diagnosis | NCIT:C80405 Transesophageal Echocardiography Test |
✅ |
| Echocardiography (generic) | NCIT:C16525 Echocardiography Test |
✅ | |
| MR angiography | Radiation-free serial surveillance, especially in young HTAD patients | NCIT:C190557 Magnetic Resonance Angiography |
✅ |
| Chest radiograph | Insensitive; may show mediastinal widening or a calcified aortic knob | — | |
| 4D-flow MRI | Research/emerging: wall shear stress mapping in BAV aortopathy | — | |
| ¹⁸F-FDG PET/CT | Aortitis and infected (mycotic) aneurysm | — |
Measurement discipline matters for KB fidelity. Guidelines require reporting the technique (leading-edge-to-leading-edge in echo; inner-edge-to-inner-edge on CT/MR), the plane (double-oblique perpendicular to the centerline), and the ECG gating status. Sinus-of-Valsalva measurements should use cusp-to-commissure or cusp-to-cusp conventions consistently across serial studies. Z-scores (age/sex/BSA-adjusted) are mandatory in pediatrics and used throughout Marfan management.
Size normalization metrics: - Aortic size index (ASI) = diameter (cm) / BSA (m²) — the standard in Turner syndrome. - Aortic height index (AHI) = diameter (cm) / height (m). - Cross-sectional area / height ratio (cm²/m) — the 2022 ACC/AHA-endorsed alternative threshold; >10 cm²/m supports intervention.
Aortic tissue is obtained at surgery, not by pre-operative biopsy. Findings, per the Society for Cardiovascular Pathology / AECVP consensus (PMID:27031798): - Medial degeneration (the preferred term): elastic fiber fragmentation and loss, mucoid ECM accumulation (translamellar and intralamellar), SMC nuclei loss, laminar medial collapse. - Grading is semiquantitative (mild/moderate/severe) for each component. - Movat pentachrome / Verhoeff-van Gieson stains for elastin, Alcian blue for GAGs. - Aortitis subtypes: granulomatous with giant cells (GCA/Takayasu), lymphoplasmacytic with storiform fibrosis and obliterative phlebitis (IgG4-RD), obliterative endarteritis of vasa vasorum with plasma cells (syphilis), suppurative (bacterial). - Immunohistochemistry: loss of ACTA2/SM-MHC staining in contractile-gene disease; IgG4/IgG plasma-cell ratio; CD68 macrophage burden.
Not diagnostic for TAA. ECG is obtained in suspected dissection primarily to detect coronary-ostial involvement (inferior STEMI pattern from right-coronary ostial dissection) and to exclude ACS as an alternative diagnosis — IRAD found the "initial chest radiograph and electrocardiogram were frequently not helpful (no abnormalities were noted in 12.4% and 31.3% of patients, respectively)" (PMID:10685714).
NCIT:C15709 Genetic Testing ✅.
Recommended approach (2022 ACC/AHA, PMID:36334952; 2024 EACTS/STS, PMID:38416090 — paraphrase, verify before quoting): - Offer genetic testing to any patient with aortic root/ascending aneurysm or aortic dissection who has: syndromic features; a family history of TAAD or unexplained sudden death; young age at presentation (<60 y); or the combination with other arteriopathy. - Multigene panel (an HTAD panel of the 11 definitive/strong ClinGen genes plus the moderate-evidence genes) is the first-line test — this is precisely why the ClinGen curation (PMID:30071989) was performed. - Whole-exome sequencing (WES) — reserved for panel-negative, strongly familial cases; the discovery route for LTBP3 (PMID:29625025), PRKG1 (PMID:23910461), and THSD4 (PMID:32855533). - Whole-genome sequencing (WGS) — research/tertiary use; the discovery route for the LOX founding family (PMID:27432961). Adds deep-intronic and structural-variant detection. - Single-gene testing — only when the familial variant is known (cascade testing) or the phenotype is unambiguous (e.g. classic Marfan → FBN1). - Del/dup analysis (MLPA) — required alongside sequencing for FBN1 and COL3A1. - Chromosomal microarray — for syndromic presentations, 16p13.1 duplication, and contiguous-gene deletions of FBN1. - Karyotype — indicated in any female with unexplained aortic dilation and short stature, to detect 45,X Turner syndrome and mosaic variants. - FISH — 22q11.2 if conotruncal features are present. - mtDNA testing / repeat-expansion testing — not applicable to TAA.
Cascade family screening is as important as proband testing: guidelines recommend aortic imaging for all first-degree relatives of a TAAD proband, and genotype-directed release from surveillance for variant-negative relatives when a pathogenic familial variant is identified. Albornoz et al. (PMID:16996941): "Screening of first-order relatives of probands with TAA is essential."
Criteria. There is no separate diagnostic criteria set for TAA itself (it is an imaging diagnosis). The relevant criteria sets are for the underlying syndromes: - Revised Ghent nosology (2010) for Marfan syndrome — aortic root Z ≥2 plus ectopia lentis, or plus a causal FBN1 variant, or plus systemic score ≥7. - 2017 International Classification of the Ehlers-Danlos Syndromes for vascular EDS. - Loeys-Dietz — clinical gestalt plus a pathogenic variant in one of the six TGF-β-pathway genes; no scored criteria. - Aortic Dissection Detection Risk Score (ADD-RS) for triage of suspected acute dissection.
Differential diagnosis:
| Alternative | Distinguishing features |
|---|---|
| Aortic pseudoaneurysm | Contained rupture; lacks all three wall layers; irregular neck; post-traumatic/post-surgical |
| Intramural hematoma | Crescentic wall thickening without an intimal flap or false-lumen flow |
| Penetrating atherosclerotic ulcer | Focal ulcer crater with adjacent atheroma; usually descending |
| Aortic dissection with chronic dilation | Intimal flap; true/false lumen |
| Aortic coarctation with post-stenotic dilation | Gradient; rib notching |
| Aortic tortuosity/elongation in the elderly | Elongation without true caliber increase |
| Mediastinal mass mimicking aneurysm on CXR | CT resolves |
| Aortitis (GCA, Takayasu, IgG4, syphilis) | Circumferential wall thickening, mural enhancement, elevated inflammatory markers, FDG uptake |
| Mycotic aneurysm | Saccular, rapidly enlarging, periaortic gas/fat stranding, fever, positive cultures |
| Homocystinuria (CBS deficiency) | Marfanoid habitus, downward lens dislocation, thrombosis, intellectual disability, elevated homocysteine |
| Congenital contractural arachnodactyly (FBN2) | Marfanoid with contractures, crumpled ears; aortic dilation mild/rare |
| MASS phenotype / familial ectopia lentis | Marfan-overlapping without progressive root dilation |
| Outcome | Value | Source |
|---|---|---|
| Untreated TAA, 5-year survival | 54% (Yale cohort, unoperated) | PMID:11834007 |
| Population 5-year survival (1980–1994) | 56% (95% CI 48–66%), improved from 19% in 1951–1980 | PMID:9851478 |
| Post-operative survival (Sweden) | 92% / 77% / 57% at 1 / 5 / 10 years | PMID:17145990 |
| 30-day operative mortality (Sweden, all-comers incl. emergency) | 16% (389/2455) | PMID:17145990 |
| Contemporary elective root/ascending repair mortality (experienced centers) | ~1–3%; valve-sparing root replacement in Marfan ~1% | Single-center series (e.g. early mortality 0.96%) |
| Acute type A dissection, overall in-hospital mortality | 27.4% | PMID:10685714 |
| Type A, surgical | 26% | PMID:10685714 |
| Type A, medical management | 58% | PMID:10685714 |
| Type B, medical management | 10.7% | PMID:10685714 |
| Type B, surgical | 31.4% | PMID:10685714 |
| Vascular EDS median survival | 48 years | PMID:10706896 |
| Untreated Marfan (historical, pre-surgical era) | ~32 years; now approaching normal with root repair | Classic literature |
Elective repair is the single most powerful prognostic modifier. Davies et al. (PMID:11834007):
"Elective, preemptive surgical repair restored life expectancy to normal."
"Thoracic aneurysm is a lethal disease; aneurysm size has a profound impact on rupture, dissection, and death; for counseling purposes, the patient with an aneurysm exceeding 6 cm can expect a yearly rate of rupture or dissection of at least 6.9% and a death rate of 11.8%; and elective surgical repair restores survival to near normal."
Aortic dissection (HP:0002647 ✅) → cardiac tamponade, aortic regurgitation (HP:0001659 ✅), myocardial infarction, stroke (HP:0002140 ✅), mesenteric/renal/limb malperfusion, paraplegia; aortic rupture (HP:0031649 ✅) → hemothorax, hemopericardium, exsanguination; aorto-bronchial fistula → hemoptysis (HP:0002105 ✅); aorto-esophageal fistula → hematemesis; compression syndromes (hoarseness HP:0001609 ✅, dysphagia HP:0002015 ✅, SVC obstruction, tracheal compression); mural thrombus with distal embolization; heart failure from chronic aortic regurgitation; sudden death (HP:0001699 ✅).
Recovery potential: the aneurysmal segment does not recover — surgical replacement is definitive for that segment only. The rest of the aorta continues on its natural history.
Established prognostic factors: - Maximal diameter (strongest single factor; PMID:11834007, PMID:9851478) — with the crucial caveat that it under-identifies dissection risk (PMID:17709637). - Growth rate — ≥0.3 cm/yr over two consecutive years, or ≥0.5 cm in one year, is an intervention trigger. - Genotype — TGFBR1/2, ACTA2 (especially R179), MYLK, PRKG1, and COL3A1 confer higher event risk at smaller diameters; this drives genotype-specific surgical thresholds. - Indexed size — ASI, aortic height index, cross-sectional area/height ratio; especially important in women, short stature, and Turner syndrome. - Family history of dissection at small diameter — an independent trigger for earlier repair. - Hypertension (PMID:17709637: OR 2.17 for dissection at <5.5 cm), female sex (PMID:9851478: 79% of ruptures), increasing age, saccular morphology, symptoms (pain = impending rupture until proven otherwise), planned pregnancy, concomitant cardiac surgery.
Prognostic biomarkers: none validated. Investigational: D-dimer (acute), MMP-9, TGF-β1, sST2, and imaging-derived biomechanical indices (peak wall stress, aortic strain/distensibility, pulse wave velocity — reduced distensibility predicts faster growth in Marfan, PMID:29631804). Machine-learning models combining geometry, biomechanics, and genotype are an active research direction and would be a good PHENOTYPE_ALGORITHM / derivation_basis: MECHANISTIC_HYPOTHESIS candidate.
NCIT:C15986 Pharmacotherapy ✅ is the correct generic treatment_term; pair with therapeutic_agent.
| Treatment | Agent term | Mechanism | Evidence |
|---|---|---|---|
| β-blockade (atenolol, metoprolol, bisoprolol) | CHEBI:2904 atenolol ✅; CHEBI:6904 metoprolol ✅; class NCIT:C29576 Beta-Adrenergic Antagonist ✅ |
Reduces dP/dt and heart rate → lower pulsatile wall stress | Long-standing standard of care; PMID:25405392, PMID:36049495 |
| ARB (losartan, irbesartan) | CHEBI:6541 losartan ✅; CHEBI:5959 irbesartan ✅; class NCIT:C66930 Angiotensin II Receptor Antagonist ✅ |
AT1R blockade → reduced TGF-β signaling + afterload reduction | PMID:16601194 (mouse), PMID:23999449, PMID:25405392, PMID:36049495 |
| Strict BP control (target <130/80 mmHg) | multi-agent | Reduces wall stress | Guideline (PMID:36334952) |
| Statins | e.g. atorvastatin | Pleiotropic/anti-remodeling | Observational only; not a TAA indication |
| Avoid fluoroquinolones | — | ECM/MMP toxicity | PMID:29519881, PMID:30046809 |
| ACE inhibitors | — | Alternative if ARB intolerant | Weaker evidence than ARB |
| Verapamil/diltiazem | — | If β-blocker intolerant | Second-line |
The definitive medical-therapy evidence. The Pediatric Heart Network trial (PMID:25405392, paraphrase: 608 children and young adults with Marfan syndrome randomized to losartan vs atenolol at 21 centers, 2007–2011) found no significant difference in the rate of aortic-root Z-score change over 3 years between the two drugs, and no difference in aortic surgery, dissection, or death. A short verbatim fragment: "Aortic-root dissection is the leading cause of death in Marfan's syndrome. Studies suggest that with regard to slowing aortic-root enlargement, losartan may be more effective than beta-blockers, the current standard therapy in most centers."
COMPARE (PMID:23999449, paraphrase, verbatim fragment): "Aortic root dilatation rate after 3.1 ± 0.4 years of follow-up was significantly lower in the losartan group than in controls" (0.77 vs 1.35 mm), in 233 adults, with no difference in the composite clinical endpoint.
The Marfan Treatment Trialists' Collaboration individual-patient-data meta-analysis (PMID:36049495, paraphrase with verbatim fragments) reconciled the trials:
"Angiotensin receptor blockers (ARBs) and β blockers are widely used in the treatment of Marfan syndrome to try to reduce the rate of progressive aortic root enlargement characteristic of this condition, but their separate and joint effects are uncertain."
"We identified ten potentially eligible trials including 1836 patients from our search, from which seven trials and 1442 patients were eligible for inclusion in our main analyses."
"During a median follow-up of 3 years, allocation to ARB approximately halved the annual rate of change in the aortic root Z score."
"combination therapy with both ARBs and β blockers from the time of diagnosis would provide even greater reductions in the rate of aortic enlargement than either treatment alone"
Current practice conclusion: ARB and β-blocker each roughly halve the rate of aortic root Z-score progression relative to no treatment; their effects appear independent and likely additive, supporting combination therapy in Marfan syndrome. Extrapolation to non-Marfan HTAD and sporadic TAA is by inference, not direct evidence.
NCIT:C15329 Surgical Procedure ✅; NCIT:C157839 Endovascular Aneurysm Repair ✅; NCIT:C50815 Aortic Valve Replacement ✅.
| Procedure | Indication | Notes |
|---|---|---|
| Valve-sparing aortic root replacement (David reimplantation; Yacoub remodeling) | Root aneurysm with a normal/repairable valve, esp. young HTAD patients | Preferred in Marfan; avoids anticoagulation. Reported early mortality <1%; ~91% survival at 10 y, 76% at 20 y; freedom from valve reoperation 86% at 10 y, 80% at 20 y (single-center series — verify PMIDs) |
| Composite valve-graft (Bentall) replacement | Root aneurysm with an unrepairable/diseased valve | Mechanical (lifelong warfarin) or bioprosthetic (structural degeneration) |
| Supracoronary ascending aortic replacement | Ascending aneurysm sparing the root | Simpler; leaves the root at risk in HTAD |
| Hemiarch / total arch replacement, frozen elephant trunk | Arch involvement | Requires hypothermic circulatory arrest ± antegrade cerebral perfusion |
| Open descending/thoracoabdominal repair | Extensive descending disease, connective tissue disease | Crawford extents I–IV; CSF drainage for cord protection |
| TEVAR (thoracic endovascular aortic repair) | Descending TAA, complicated type B dissection, penetrating ulcer, traumatic transection | Relatively contraindicated as definitive therapy in HTAD (Marfan/LDS/vEDS) because the diseased native aorta is a poor landing zone; used as a bridge in emergencies |
| Branched/fenestrated endografts, TAMBE | Arch and thoracoabdominal extension | Growing, high-volume-center technique |
| Emergency ascending replacement | Acute type A dissection | Surgical emergency; ~1–2%/hour mortality untreated |
Thresholds (2022 ACC/AHA, PMID:36334952 — paraphrase; verify each before curating): ≥5.5 cm for sporadic/degenerative ascending aneurysm (Class 1); ≥5.0 cm at experienced multidisciplinary aortic-team centers (Class 2a); ≥5.0 cm in Marfan syndrome (with 4.5 cm considered where there is a family history of early dissection, rapid growth, or planned pregnancy); ≥4.5 cm for TGFBR1/TGFBR2 Loeys-Dietz; ≥4.5 cm for ACTA2 and other high-risk genotypes; concomitant repair at ≥4.5 cm when the patient is already undergoing aortic valve or other cardiac surgery; growth ≥0.3 cm/yr over two consecutive years or ≥0.5 cm in one year; cross-sectional-area-to-height ratio >10 cm²/m; ≥5.5 cm (endovascular) or ≥6.0 cm (open) for descending TAA. A major structural recommendation of the 2022 guideline is the multidisciplinary aortic team and referral to high-volume centers.
antisense_oligonucleotide_therapy module's RNase-H paradigm would fit.NCIT:C15747 Supportive Care ✅; NCIT:C15372 Smoking Cessation Intervention ✅; NCIT:C15240 Genetic Counseling ✅.
NCIT:C15302 Physical Therapy.Active and recent directions (obtain and verify NCT numbers before curating a clinical_trials block):
- Combination ARB + β-blocker versus monotherapy in Marfan (the direct implication of PMID:36049495).
- Irbesartan in Marfan (AIMS trial, UK — completed; showed reduced aortic root growth).
- Resveratrol in Marfan (single-arm, PMID:39317438).
- Rapamycin/sirolimus and mTOR inhibition — preclinical to early phase.
- Rifampicin, doxycycline, and other MMP-directed repurposing — largely negative.
- TEVAR versus optimal medical therapy in uncomplicated type B dissection (ADSORB, INSTEAD-XL legacy; ongoing successors).
- AI/biomechanics-guided intervention timing (observational).
Aneurysm detected
├─ Determine etiology: syndromic features? family history? BAV? aortitis? infection?
├─ Genetic testing (HTAD panel) if young / familial / syndromic
├─ ALL: BP <130/80, β-blocker ± ARB, smoking cessation, activity counseling,
│ avoid fluoroquinolones, serial imaging (interval set by size + genotype)
├─ Cascade imaging ± genotype screening of first-degree relatives
└─ Meets threshold (size / indexed size / growth / genotype / symptoms /
planned pregnancy / concomitant cardiac surgery)?
├─ Ascending/root → open repair (valve-sparing preferred if valve is good)
├─ Arch → hemiarch/total arch ± FET
└─ Descending → TEVAR (avoid as definitive therapy in HTAD) or open repair
Aortitis arm → immunosuppression (steroids, tocilizumab, MTX, rituximab)
Mycotic arm → prolonged targeted antimicrobials + debridement/repair
Personalized medicine is already real here: surgical thresholds are formally genotype-stratified, which makes TAA one of the clearest examples of genomically guided procedural timing in cardiovascular medicine.
Not applicable to TAA pathogenesis. Routine adult vaccination (influenza, pneumococcal, COVID-19, RSV) is standard perioperative and cardiovascular care.
NCIT:C15240 Genetic Counseling ✅.Prophylactic aortic surgery is the prophylaxis — pre-emptive replacement of the aneurysmal segment before it dissects. This is the concept Davies et al. captured (PMID:11834007): "This analysis strongly supports careful radiologic follow-up and elective, preemptive surgical intervention for the otherwise lethal condition of large thoracic aortic aneurysm." Pre-pregnancy prophylactic root replacement in Marfan women with a 4.0–4.5 cm root is a specific and well-established application.
| Species | NCBI Taxon | Natural disease | Notes |
|---|---|---|---|
| Dog (Canis lupus familiaris) | NCBITaxon:9615 | Spontaneous dissecting aortic aneurysm — rare, case-report level (e.g. PMID:12683625, "Aortic dissection associated with aortic aneurysms and posterior paresis in a dog"). MONDO recognizes MONDO:1012381 familial thoracic aortic aneurysm, dog ✅ |
Rare; often presents with posterior paresis from aortoiliac involvement |
| Cat (Felis catus) | NCBITaxon:9685 | Dissecting aortic aneurysm, often with systemic hypertension (PMID:29717986) | Rare |
| Horse (Equus caballus) | NCBITaxon:9796 | Aortic root rupture in breeding stallions; aorto-pulmonary/aorto-cardiac fistula — a recognized and fatal syndrome | The best-characterized large-animal spontaneous aortic rupture |
| Turkey (Meleagris gallopavo) | NCBITaxon:9103 | Spontaneous dissecting aortic aneurysm of male turkeys — a classic agricultural disease; strongly modulated by copper status and by β-aminopropionitrile (lathyrogen) exposure | Direct comparative counterpart of human LOX loss-of-function |
| Chicken (Gallus gallus) | NCBITaxon:9031 | Copper-deficiency aortic rupture | Foundational to the discovery of lysyl oxidase biology |
| Cattle (Bos taurus) | NCBITaxon:9913 | Bovine Marfan syndrome — an autosomal dominant FBN1-associated syndrome with aortic dilation, described in Holstein cattle (OMIA) | A genuine naturally occurring Marfan model |
| Non-human primates | NCBITaxon:9539 (macaque) etc. | Sporadic aortic aneurysm/dissection reported | Rare |
Per the Merck Veterinary Manual, aneurysms are rare in domestic animal species but have been reported in dogs, cats, horses, primates, turkeys, reptiles, and other exotic species.
Fbn1 (14118), Tgfbr1 (21812), Tgfbr2 (21813), Smad3 (17127), Tgfb2 (21808), Acta2 (11475), Myh11 (17880), Mylk (107589), Prkg1 (19091), Lox (16948), Col3a1 (12825), Thsd4 (207596), Notch1 (18128). All are single-copy, high-identity orthologs — the pathway is deeply conserved. Alliance of Genome Resources and HomoloGene are the reference resources.
Not applicable — TAA is non-communicable and non-zoonotic. The only pathogen-linked forms (syphilitic, salmonella mycotic) involve organisms that are separately zoonotic or human-restricted; the aneurysm itself is not transmissible.
| Model | Lesion | Phenotype recapitulation | Key limitation | Reference |
|---|---|---|---|---|
| Fbn1^C1039G/+ | Knock-in cysteine substitution, dominant negative | Progressive aortic root aneurysm, elastic fiber fragmentation, SMC disarray, excess collagen/proteoglycan; skeletal and pulmonary Marfan features after ~2 months; >90% survival at 8 months | Rarely dissects or ruptures — models dilation, not the lethal event | PMID:15254584; PMID:16601194 |
| Fbn1^mgR/mgR | Hypomorphic allele (~15–25% normal fibrillin-1) | Severe, rapidly enlarging root aneurysm with dissection/rupture and early death; the standard survival-endpoint model | Homozygous hypomorph is not the human genotype | PMID:25614286 |
| Fbn1^C1039G/C1039G | Homozygous | Perinatal death from aortic dissection | Not viable for longitudinal study | — |
| Tgfbr1^M318R/+, Tgfbr2^G357W/+ | Knock-in LDS alleles | Aortic root dilation with increased pSmad2 and pERK, elastin fragmentation — reproduces the LDS paradox | Milder than human LDS | Gallo et al., JCI 2014 (retrieve PMID) |
| Tgfbr1^+/− (haploinsufficient) | Null allele | No cardiovascular phenotype — argues against simple haploinsufficiency | Negative result, informative | PMC3933654 (retrieve PMID) |
| Tgfb2^+/− | Haploinsufficiency | Aortic root aneurysm with increased canonical and noncanonical TGF-β signaling; worsens Fbn1^C1039G/+ | — | PMID:22772368 |
| Smad3^−/− | Null | Aortic dilation, dissection, medial degeneration, plus osteoarthritis (matching the human AOS phenotype) | Recessive in mouse, dominant in human | PMID:21217753 |
| Thsd4^+/− | Haploinsufficiency | "Thsd4+/- mice showed progressive dilation of the thoracic aorta"; medial degeneration and diffuse ECM disruption on histology | Mild | PMID:32855533 |
| Lox knock-in (human allele) | Missense | "Mice homozygous for the human allele died shortly after parturition from ascending aortic aneurysm and spontaneous hemorrhage"; disorganized aortic wall ultrastructure | Homozygous lethality limits adult study | PMID:27432961 |
| SMC-specific Mylk knockdown | Conditional | "mice with SMC-specific knockdown of Mylk demonstrate altered gene expression and pathology consistent with medial degeneration of the aorta" | Knockdown, not the human point mutation | PMID:21055718 |
| Acta2^−/−, Acta2^R149C/+, Myh11^R247C/+ | Contractile-gene knock-in/knockout | Impaired contractility, medial changes; generally require a hemodynamic second hit (AngII infusion) to produce frank aneurysm | Weak baseline phenotype | Milewicz lab series |
| Col3a1^+/− and knock-in | vEDS alleles | Spontaneous arterial rupture and death | Very fragile animals | — |
| Fbln4/Efemp2 SMC-conditional KO | Elastogenesis defect | Ascending aortic aneurysm and tortuosity | Recessive/conditional | — |
fbn2b/fibrillin and tgfbr morphants and mutants for developmental vascular patterning; rapid, transparent, good for variant functional screening; but no comparable high-pressure ascending aorta, so it cannot model the mechanical disease.HUMAN_MODEL_MISMATCH curation)HUMAN_MODEL_MISMATCH case for this disease.MGI (mouse), IMPC/KOMP (null alleles for all HTAD genes), IMSR and JAX (Fbn1^C1039G/+ is JAX #012885; Fbn1^mgR is available), MMRRC, EMMA, RGD (rat BAPN models), ZFIN (zebrafish), Cellosaurus/ATCC (human aortic SMC lines), Alliance of Genome Resources, and OMIA for the bovine Marfan and turkey aortic-rupture entries.
MONDO: MONDO:0005396 thoracic aortic aneurysm ✅ (primary disease_term); MONDO:0019625 familial thoracic aortic aneurysm and aortic dissection ✅ (subtype/grouping mapping).
HPO (all OAK-verified): HP:0012727 Thoracic aortic aneurysm · HP:0004942 Aortic aneurysm · HP:0002616 Aortic root aneurysm · HP:0004970 Ascending tubular aorta aneurysm · HP:0012728 Fusiform descending thoracic aortic aneurysm · HP:0012729 Saccular descending thoracic aortic aneurysm · HP:0002647 Aortic dissection · HP:0031649 Aortic rupture · HP:0001659 Aortic regurgitation · HP:0001647 Bicuspid aortic valve · HP:0001634 Mitral valve prolapse · HP:0001643 Patent ductus arteriosus · HP:0005116 Arterial tortuosity · HP:0005112 Abdominal aortic aneurysm · HP:0000822 Hypertension · HP:0100749 Chest pain · HP:0001609 Hoarse voice · HP:0002015 Dysphagia · HP:0002105 Hemoptysis · HP:0001279 Syncope · HP:0001699 Sudden death · HP:0002140 Ischemic stroke · HP:0002326 Transient ischemic attack.
UBERON (all OAK-verified): UBERON:0001515 thoracic aorta · UBERON:0001496 ascending aorta · UBERON:0001508 arch of aorta · UBERON:0003707 sinus of Valsalva · UBERON:0000947 aorta · UBERON:0002137 aortic valve · UBERON:0003618 aorta tunica media · UBERON:0002522 tunica media · UBERON:0004178 aorta smooth muscle tissue · UBERON:0004237 blood vessel smooth muscle.
CL (all OAK-verified): CL:0000359 vascular associated smooth muscle cell · CL:0000192 smooth muscle cell · CL:0002139 endothelial cell of vascular tree · CL:0000057 fibroblast · CL:0000235 macrophage · CL:0000084 T cell.
GO (QuickGO-verified; re-run just validate-terms since the local GO db is corrupt): GO:0007179 transforming growth factor beta receptor signaling pathway · GO:0006939 smooth muscle contraction · GO:0030198 extracellular matrix organization · GO:0030199 collagen fibril organization · GO:0048251 elastic fiber assembly · GO:0004720 protein-lysine 6-oxidase activity · GO:0006954 inflammatory response · GO:0006979 response to oxidative stress · GO:0035904 aorta development · GO:0014909 smooth muscle cell migration.
NCIT (all OAK-verified): NCIT:C15986 Pharmacotherapy · NCIT:C29576 Beta-Adrenergic Antagonist · NCIT:C66930 Angiotensin II Receptor Antagonist · NCIT:C15329 Surgical Procedure · NCIT:C157839 Endovascular Aneurysm Repair · NCIT:C50815 Aortic Valve Replacement · NCIT:C202408 Computed Tomography Angiography · NCIT:C157338 Multi-detector Computed Tomography Angiography · NCIT:C190557 Magnetic Resonance Angiography · NCIT:C80404 Transthoracic Echocardiography Test · NCIT:C80405 Transesophageal Echocardiography Test · NCIT:C16525 Echocardiography Test · NCIT:C15709 Genetic Testing · NCIT:C15240 Genetic Counseling · NCIT:C15372 Smoking Cessation Intervention · NCIT:C15747 Supportive Care · NCIT:C49236 Therapeutic Procedure.
CHEBI (OLS4-verified): CHEBI:6541 losartan · CHEBI:2904 atenolol · CHEBI:5959 irbesartan · CHEBI:6904 metoprolol · CHEBI:100241 ciprofloxacin (risk factor, not treatment).
HGNC (genenames.org-verified; use lowercase hgnc: prefix in dismech): hgnc:3603 FBN1 · hgnc:11772 TGFBR1 · hgnc:11773 TGFBR2 · hgnc:6769 SMAD3 · hgnc:11768 TGFB2 · hgnc:11769 TGFB3 · hgnc:130 ACTA2 · hgnc:7569 MYH11 · hgnc:7590 MYLK · hgnc:9414 PRKG1 · hgnc:6664 LOX · hgnc:2201 COL3A1 · hgnc:13444 SLC2A10 · hgnc:10896 SKI · hgnc:3219 EFEMP2 · hgnc:29673 MFAP5 · hgnc:3808 FOXE3 · hgnc:25835 THSD4 · hgnc:6716 LTBP3 · hgnc:7881 NOTCH1 · hgnc:1044 BGN · hgnc:3327 ELN · hgnc:3754 FLNA · hgnc:6768 SMAD2 · hgnc:6770 SMAD4 · hgnc:6904 MAT2A.
| PMID | First author, year | Journal | Content | Evidence source |
|---|---|---|---|---|
| 36334952 | Isselbacher EM, 2022 | JACC | 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease | HUMAN_CLINICAL |
| 38416090 / 38408364 | Czerny M, 2024 | Ann Thorac Surg / EJCTS | EACTS/STS Guidelines for the aortic organ | HUMAN_CLINICAL |
| 30071989 | Renard M, 2018 | JACC | ClinGen clinical validity of HTAAD genes | OTHER (expert curation) |
| 30763214 | Pinard A, 2019 | Circ Res | Genetics of thoracic and abdominal aortic diseases (review) | OTHER |
| 27297344 | Isselbacher EM, 2016 | Circulation | Hereditary influence in TAAD (review) | OTHER |
| 37308786 | (MVP), 2023 | Nat Genet | GWAS of TAAD in the Million Veteran Program; 21 loci | HUMAN_CLINICAL |
| 34837083 | Pirruccello JP, 2022 | Nat Genet | Deep learning genetic analysis of the thoracic aorta | HUMAN_CLINICAL |
| 17994018 | Guo DC, 2007 | Nat Genet | ACTA2 mutations cause TAAD (14% of inherited TAAD) | HUMAN_CLINICAL |
| 16444274 | Zhu L, 2006 | Nat Genet | MYH11 mutations, TAAD + PDA, dominant negative | HUMAN_CLINICAL |
| 21055718 | Wang L, 2010 | AJHG | MYLK mutations cause familial aortic dissections | HUMAN_CLINICAL |
| 23910461 | Guo DC, 2013 | AJHG | PRKG1 R177Q gain-of-function | HUMAN_CLINICAL |
| 27432961 | Lee VS, 2016 | PNAS | LOX loss-of-function causes TAAD | HUMAN_CLINICAL / MODEL_ORGANISM |
| 32855533 | Elbitar S, 2021 | Genet Med | THSD4/ADAMTSL6 haploinsufficiency | HUMAN_CLINICAL / MODEL_ORGANISM |
| 29625025 | Guo DC, 2018 | AJHG | LTBP3 pathogenic variants predispose to TAAD | HUMAN_CLINICAL |
| 15731757 | Loeys BL, 2005 | Nat Genet | TGFBR1/TGFBR2 — Loeys-Dietz syndrome | HUMAN_CLINICAL |
| 21217753 | van de Laar IM, 2011 | Nat Genet | SMAD3 — aneurysms-osteoarthritis syndrome | HUMAN_CLINICAL |
| 22772368 | Lindsay ME, 2012 | Nat Genet | TGFB2 loss of function; the TGF-β paradox | HUMAN_CLINICAL / MODEL_ORGANISM |
| 12598898 | Neptune ER, 2003 | Nat Genet | Dysregulated TGF-β activation in Marfan | MODEL_ORGANISM |
| 16601194 | Habashi JP, 2006 | Science | Losartan prevents aortic aneurysm in Marfan mice | MODEL_ORGANISM |
| 15254584 | Judge DP, 2004 | JCI | Haploinsufficiency in Marfan pathogenesis | MODEL_ORGANISM |
| 25614286 | Cook JR, 2015 | ATVB | Dimorphic TGF-β effects; combinatorial therapy | MODEL_ORGANISM |
| 20734336 | Milewicz DM, 2010 | Am J Med Genet A | ACTA2 R179H multisystemic smooth muscle dysfunction | HUMAN_CLINICAL |
| 16025100 | Garg V, 2005 | Nature | NOTCH1 mutations cause aortic valve disease | HUMAN_CLINICAL |
| 10706896 | Pepin M, 2000 | NEJM | Vascular EDS natural history; median survival 48 y | HUMAN_CLINICAL |
| 16996941 | Albornoz G, 2006 | Ann Thorac Surg | Familial TAA: 21.5% inherited, AD 76.9%, growth rates | HUMAN_CLINICAL |
| 11834007 | Davies RR, 2002 | Ann Thorac Surg | Yearly rupture/dissection rates by size | HUMAN_CLINICAL |
| 9851478 | Clouse WD, 1998 | JAMA | Olmsted County incidence 10.4/100,000; rupture by size | HUMAN_CLINICAL |
| 17145990 | Olsson C, 2006 | Circulation | Swedish national registry, >14,000 cases | HUMAN_CLINICAL |
| 10685714 | Hagan PG, 2000 | JAMA | IRAD: presentation and mortality of acute dissection | HUMAN_CLINICAL |
| 17709637 | Pape LA, 2007 | Circulation | 59% of type A dissections at <5.5 cm | HUMAN_CLINICAL |
| 33017217 | Li Y, 2020 | Circulation | scRNA-seq of human ascending TAA; 11 cell types, 40 subtypes | HUMAN_CLINICAL / IN_VITRO |
| 27031798 | Halushka MK, 2016 | Cardiovasc Pathol | SCVP/AECVP consensus on noninflammatory degenerative aortic pathology | OTHER |
| 25405392 | Lacro RV, 2014 | NEJM | Atenolol vs losartan in Marfan (PHN trial) | HUMAN_CLINICAL |
| 23999449 | Groenink M, 2013 | Eur Heart J | COMPARE: losartan reduces aortic dilatation rate | HUMAN_CLINICAL |
| 36049495 | Pitcher A, 2022 | Lancet | ARB + β-blocker IPD meta-analysis in Marfan | HUMAN_CLINICAL |
| 39317438 | van Andel MM, 2024 | Heart | Resveratrol single-arm trial in Marfan | HUMAN_CLINICAL |
| 29519881 | Pasternak B, 2018 | BMJ | Fluoroquinolones and aortic aneurysm/dissection | HUMAN_CLINICAL |
| 30046809 | LeMaire SA, 2018 | JAMA Surg | Ciprofloxacin and aortic dissection in mice | MODEL_ORGANISM |
| 20829218 | Gomez D, 2011 | Cardiovasc Res | Epigenetic control of SMC in Marfan/non-Marfan TAA | IN_VITRO / HUMAN_CLINICAL |
| 23814118 | Gomez D, 2013 | ATVB | Smad2-dependent PN-1; aneurysm vs dissection | HUMAN_CLINICAL |
| 26005802 | Franken R, 2015 | Int J Cardiol | Aortic tortuosity as a Marfan severity marker | HUMAN_CLINICAL |
| 29631804 | Selamet Tierney ES, 2018 | Am J Cardiol | Aortic stiffness predicts root growth in Marfan | HUMAN_CLINICAL |
| 36345977 | Oudin Åström D, 2022 | Glob Health Action | Temperature and incidence of surgery for type A dissection | HUMAN_CLINICAL |
| 12683625 | Waldrop JE, 2003 | J Vet Intern Med | Aortic dissection with aneurysms and posterior paresis in a dog | MODEL_ORGANISM |
| 29717986 | — , 2018 | (vet) | Dissecting aortic aneurysm with hypertension in a cat | MODEL_ORGANISM |
conforms_to: "aortopathy_tgfbeta_dysregulation#TGF-beta Signaling Dysregulation" plus the medial-degeneration and progressive-dilation nodes. Do not conform to atherogenesis — PMID:37308786 explicitly establishes TAAD as non-atherosclerotic and distinct from other vascular disease. A thrombogenesis link is defensible only for false-lumen/mural thrombus nodes.Heritable_Thoracic_Aortic_Disease grouping; the heritable subtypes of this entry should be consistent with its NECESSARY nested AND/OR phenotype criterion.mechanistic_hypotheses with a stable hypothesis_group_id (e.g. tgfb_excess_drives_aneurysm) and opt the relevant downstream[].hypothesis_groups edges into it. Add a discussions entry with kind: HUMAN_MODEL_MISMATCH for the losartan mouse-to-human translation failure (PMID:16601194 → PMID:25405392), and a KNOWLEDGE_GAP for the unresolved direction-of-effect question (PMID:25614286, PMID:22772368).measure_type: ANNUAL_INCIDENCE for the Olmsted/Swedish figures with rate_per_100000 set to 10.4 / 16.3 / 9.1 — do not enter these as point prevalence.name values): Sporadic, FTAAD, Marfan, LDS, vEDS, BAV-Aortopathy, Aortitis, Mycotic, MSMDS (ACTA2 R179).biological_scale tags: MOLECULAR for the fibrillin/TGF-β/actomyosin nodes; CELLULAR for SMC apoptosis and phenotypic modulation; TISSUE for medial degeneration and elastic fiber fragmentation; ORGANISM for dilation, dissection, rupture, and death.frequency: enum to a phenotype unless the cited abstract carries the number — several of the abstracts here do (e.g. 21.5% familial, 14% ACTA2, 59% <5.5 cm, 27.4% mortality) and those are legitimately quotable.just fetch-reference PMID:xxxxx and validated with just validate-references before being used as evidence snippet: values. Everything shown in full blockquote form was retrieved verbatim from efetch.Sources:
- PubMed E-utilities (esearch/esummary/efetch)
- 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease — PubMed · PMC full text
- EACTS/STS Guidelines for Diagnosing and Treating Acute and Chronic Syndromes of the Aortic Organ — PubMed
- Genome-wide association study of TAAD in the Million Veteran Program — Nature Genetics
- Deep learning enables genetic analysis of the human thoracic aorta — Nature Genetics
- Current understanding of the genetics of thoracic aortic disease — PMC
- Heritable Thoracic Aortic Disease Overview — GeneReviews
- Angiotensin receptor blockers and β blockers in Marfan syndrome — The Lancet
- Thrombosis, Embolism, Aneurysm, and Dissection in Animals — Merck Veterinary Manual
- Valve-sparing aortic root replacement (David I) in Marfan disease — EJCTS
- QuickGO · OLS4 · HGNC REST · local OAK (sqlite:obo:hp, uberon, cl, ncit, mondo)